




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 48/00	A2	(11) International Publication Number: WO 00/54813 (43) International Publication Date: 21 September 2000 (21.09.00)
<p>(21) International Application Number: PCT/US00/07062</p> <p>(22) International Filing Date: 15 March 2000 (15.03.00)</p> <p>(30) Priority Data: 60/124,460 15 March 1999 (15.03.99) US 60/174,984 6 January 2000 (06.01.00) US</p> <p>(71) Applicants (for all designated States except US): CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): MANNING, William, C., Jr. [US/US]; 3660 Country Club Drive, Redwood City, CA 94061 (US). DWARKI, Varavani, J. [US/US]; 1177 Old Alameda Point, Alameda, CA 94502 (US). RENDAHL, Katherine [US/US]; 1221 Grizzly Peak Boulevard, Berkeley, CA 94708 (US). ZHOU, Shang-Zhen [US/US]; 125 Fundy Bay, Alameda, CA 94502 (US). MCGEE, Laura, H. [US/US]; 652 54th Street, Oakland, CA 94609 (US). LAU, Dana [US/US]; Apartment A, 280 Lenox Avenue, Oakland, CA 94610 (US). FLANNERY, John, G. [US/US]; 1728 Marin Avenue, Berkeley, CA 94707 (US). MILLER,</p>		<p>Sheldon [US/US]; 186 Hillcrest Road, Berkeley, CA 94705 (US). WANG, Fei [CN/US]; 981 9th Street, Albany, CA 94710 (US). DI POLO, Adriana [VE/US]; 704 Champagne Avenue, Outremont, Quebec H2V 3P8 (CA).</p> <p>(74) Agents: MCMASTERS, David, D. et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 5th Avenue, Seattle, WA 98104-7092 (US).</p> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(54) Title: USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING DISEASES OF THE EYE</p> <p style="text-align: center;">Localization of Heparin sulfate Proteoglycan, the Cellular Receptor for AAV, in the Adult Rat Retina</p>  <p>(57) Abstract</p> <p>Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING DISEASES OF THE EYE

TECHNICAL FIELD

5 The present invention relates generally to compositions and methods for treating diseases of the eye, and more specifically, to the use of various gene delivery vectors which direct the expression of selected gene products suitable for treating or preventing diseases of the eye.

BACKGROUND OF THE INVENTION

10 Eye diseases represent a significant health problem in the United States and world-wide. Presently, over 80 million Americans are affected with potentially blinding eye disease, with 1.1 million being legally blind. Twelve million individuals suffer from some degree of visual impairment that cannot be corrected. The total economic impact of eye disease is also very significant. In 1981, the estimated economic impact of visual impairment on the U.S. economy was 14 billion per year.
15 By 1995, this impact had grown to an estimated 38.4 billion (National Eye Institute NIH).

A wide variety of eye diseases can cause visual impairment, including for example, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies
20 (whether inherited, induced by surgery, trauma, a toxic compound or agent, or, photically).

One structure in the eye that can be particularly affected by disease is the retina. Briefly, the retina, which is found at the back of the eye, is a specialized light-sensitive tissue that contains photoreceptor cells (rods and cones) and neurons
25 connected to a neural network for the processing of visual information (see Figure 10). This information is sent to the brain for decoding into a visual image.

The retina depends on cells of the adjacent retinal pigment epithelium (RPE) for support of its metabolic functions. Photoreceptors in the retina, perhaps because of their huge energy requirements and highly differentiated state, are sensitive
30 to a variety of genetic and environmental insults. The retina is thus susceptible to an array of diseases that result in visual loss or complete blindness.

Retinitis pigmentosa (RP), which results in the destruction of photoreceptor cells, the RPE, and choroid typify inherited retinal degenerations. This

group of debilitating conditions affects approximately 100,000 people in the United States.

A great deal of the progress made in addressing this important clinical problem has depended on advances in research on photoreceptor cell biology, molecular biology, molecular genetics, and biochemistry over the past two decades. Animal models of hereditary retinal disease have been vital in helping unravel the specific genetic and biochemical defects that underlie abnormalities in human retinal diseases. It now seems clear that both genetic and clinical heterogeneity underlie many hereditary retinal diseases.

The leading cause of visual loss in the elderly is Age-related Macular Degeneration (AMD). The social and economic impact of this disease in the United States is increasing. The macula is a structure near the center of the retina that contains the fovea. This specialized portion of the retina is responsible for the high-resolution vision that permits activities such as reading. The loss of central vision in AMD is devastating. Degenerative changes to the macula (maculopathy) can occur at almost any time in life but are much more prevalent with advancing age. With growth in the aged population, AMD will become a more prevalent cause of blindness than both diabetic retinopathy and glaucoma combined. Laser treatment has been shown to reduce the risk of extensive macular scarring from the "wet" or neovascular form of the disease. The effects of this treatment are short-lived, however, due to recurrent choroidal neovascularization. Thus, there are presently no effective treatments in clinical use for the vast majority of AMD patients.

Other diseases of the eye, such as glaucoma, are also major public health problems in the United States. In particular, blindness from glaucoma is believed to impose significant costs annually on the U.S. Government in Social Security benefits, lost tax revenues, and healthcare expenditures.

Briefly, glaucoma is not a uniform disease but rather a heterogeneous group of disorders that share a distinct type of optic nerve damage that leads to loss of visual function. The disease is manifest as a progressive optic neuropathy that, if left untreated, leads to blindness. It is estimated that as many as 3 million Americans have glaucoma and, of these, as many as 120,000 are blind as a result. Furthermore, it is the number one cause of blindness in African-Americans. Its most prevalent form, primary open-angle glaucoma, can be insidious. This form usually begins in midlife and progresses slowly but relentlessly. If detected early, disease progression can frequently be arrested or slowed with medical and surgical treatment.

Glaucoma can involve several tissues in the front and back of the eye. Commonly, but not always, glaucoma begins with a defect in the front of the eye. Fluid in the anterior portion of the eye, the aqueous humor, forms a circulatory system that brings nutrients and supplies to various tissues. Aqueous humor enters the anterior chamber via the ciliary body epithelium (inflow), flows through the anterior segment bathing the lens, iris, and cornea, and then leaves the eye via specialized tissues known as the trabecular meshwork and Schlemm's canal to flow into the venous system. Intraocular pressure is maintained *vis-à-vis* a balance between fluid secretion and fluid outflow. Almost all glaucomas are associated with defects that interfere with aqueous humor outflow and, hence, lead to a rise in intraocular pressure. The consequence of this impairment in outflow and elevation in intraocular pressure is that optic nerve function is compromised. The result is a distinctive optic nerve atrophy, which clinically is characterized by excavation and cupping of the optic nerve, indicative of loss of optic nerve axons.

Primary open-angle glaucoma is, by convention, characterized by relatively high intraocular pressures believed to arise from a blockage of the outflow drainage channel or trabecular meshwork in the front of the eye. However, another form of primary open-angle glaucoma, normal-tension glaucoma, is characterized by a severe optic neuropathy in the absence of abnormally high intraocular pressure. Patients with normal-tension glaucoma have pressures within the normal range, albeit often in the high normal range. Both these forms of primary open-angle glaucoma are considered to be late-onset diseases in that, clinically, the disease first presents itself around midlife or later. However, among African-Americans, the disease may begin earlier than middle age. In contrast, juvenile open-angle glaucoma is a primary glaucoma that affects children and young adults. Clinically, this rare form of glaucoma is distinguished from primary open-angle glaucoma not only by its earlier onset but also by the very high intraocular pressure associated with this disease. Angle-closure glaucoma is a mechanical form of the disease caused by contact of the iris with the trabecular meshwork, resulting in blockage of the drainage channels that allow fluid to escape from the eye. This form of glaucoma can be treated effectively in the very early stages with laser surgery. Congenital and other developmental glaucomas in children tend to be severe and can be very challenging to treat successfully. Secondary glaucomas result from other ocular diseases that impair the outflow of aqueous humor from the eye and include pigmentary glaucoma, pseudoexfoliative glaucoma, and glaucomas resulting from trauma and inflammatory diseases. Blockage of the outflow

channels by new blood vessels (neovascular glaucoma) can occur in people with retinal vascular disease, particularly diabetic retinopathy.

Primary open-angle glaucoma can be insidious. It usually begins in midlife and progresses slowly but relentlessly. If detected, disease progression can frequently be arrested or slowed with medical and surgical treatment. However, without treatment, the disease can result in absolute irreversible blindness. In many cases, even when patients have received adequate treatment (*e.g.*, drugs to lower intraocular pressure), optic nerve degeneration and loss of vision continues relentlessly.

The present invention provides compositions and methods for treating and preventing a number of diseases of the eye, including for example, retinal diseases and degenerations such as RP and AMD, as well as other diseases such as neovascular disease. The present invention also provides other, related advantages.

SUMMARY OF THE INVENTION

Briefly stated, the present invention provides compositions and methods for treating, preventing, or, inhibiting diseases of the eye. Within one aspect of the present invention, methods are provided for treating or preventing diseases of the eye comprising the step of intraocularly administering a gene delivery vector which directs the expression of one or more neurotrophic factors, or, anti-angiogenic factors, such that the disease of the eye is treated or prevented. Within related aspects of the present invention, gene delivery vectors are provided which direct the expression of one or more neurotrophic factors such as FGF, as well as gene therapy vectors which direct the expression of one or more anti-angiogenic factors. Within certain embodiments of the invention, a viral promoter (*e.g.*, CMV) or an inducible promoter (*e.g.*, tet) is utilized to drive the expression of the neurotrophic factor.

Representative examples of gene delivery vectors suitable for use within the present invention may be generated from viruses such as retroviruses (*e.g.*, FIV or HIV), herpesviruses, adenoviruses, adeno-associated viruses, and alphaviruses, or from non-viral vectors.

Utilizing the methods and gene delivery vectors provided herein a wide variety of diseases of the eye may be readily treated or prevented, including for example, glaucoma, macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, retinal detachment or injury and retinopathies (whether inherited, induced by surgery, trauma, a toxic compound or agent, or, photically). Similarly, a wide variety of neurotrophic factors may be utilized (either alone or in combination) within the context of the present invention, including for

example, NGF, BDNF, CNTF, NT-3, NT-4, FGF-2, FGF-5, FGF-18, FGF-20 and FGF-21.

Within certain embodiments of the invention, it is preferred that the gene delivery vector be utilized to deliver and express an anti-angiogenic factor for the treatment, prevention, or, inhibition of diabetic retinopathy, wet ARMD, and other neovascular diseases of the eye (*e.g.*, ROP). Within other embodiments it is desirable that the gene delivery vector be utilized to deliver and express a neurotrophic growth factor to treat, prevent, or, inhibit diseases of the eye, such as, for example, glaucoma, retinitis pigmentosa, and dry ARMD. Within yet other embodiments, it may be desirable to utilize either a gene delivery vector which expresses both an anti-angiogenic molecule and a neurotrophic growth factor, or two separate vectors which independently express such factors, in the treatment, prevention, or inhibition of an eye disease (*e.g.*, for diabetic retinopathy).

Within further embodiments of the invention, the above-mentioned methods utilizing gene delivery vectors may be administered along with other methods or therapeutic regimens, including for example, photodynamic therapy (*e.g.*, for wet ARMD), laser photocoagulation (*e.g.*, for diabetic retinopathy and wet ARMD), and intraocular pressure reducing drugs (*e.g.*, for glaucoma).

Also provided by the present invention are isolated nucleic acid molecules comprising the sequence of Figure 2, vectors which contain, and/or express this sequence, and host cells which contain such vectors.

Within further aspects of the present invention gene delivery vectors are provided which direct the expression of a neurotrophic factor, or, an anti-angiogenic factor. As noted above, representative examples of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, FGF-2, FGF-5, FGF-18, FGF-20 and FGF-21. Representative examples of anti-angiogenic factors include soluble Flt-1, soluble Tie-2 receptor, and PEDF. Representative examples of suitable gene delivery vectors include adenovirus, retroviruses (*e.g.*, HIV or FIV-based vectors), alphaviruses, AAV vectors, and naked DNA vectors.

These and other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings. In addition, various references are set forth herein which describe in more detail certain procedures or compositions (*e.g.*, plasmids, etc.), and are therefore incorporated by reference in their entirety.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a schematic illustration of pKm201bFGF-2.

Figure 2 is the nucleic acid sequence of pKm201bFGF-2 (SEQ I.D.

No. ____).

Figure 3 is a schematic illustration of pD10-CMV-FGF-5.

Figure 4 is a western analysis of FGF-5 rAAV infected 293 cells.

Figure 5 is a schematic illustration of pD10-CMV-FGF-5 (sig-).

Figure 6 is a western analysis of pD10-CMV-FGF-5 (sig-) transfected

293 cells.

Figure 7 is a schematic illustration of pD10-CMV-FGF-18.

Figure 8 western analysis of 293 cells transfected pD10-CMV-FGF-18.

Figures 9A and 9B are photographs which show that blueo-gal staining is visible across 40% of a retina transfected with AAV-CMV-lacZ. All photoreceptors appear to express lacZ at the injection site, except at the edge where individual cells are

visible.

Figure 10 is a schematic illustration which shows the retina within the eye, and the organization of cells within the retina.

Figures 11A and 11B are photographs of wild-type and degenerated S334ter rat retinas. S334ter is a rat model for retinitis pigmentosa.

Figures 12A, 12B and 12C are photographs of degenerated S334ter, FGF-2 injected S334ter and PBS injected S334ter rat retinas. As can be seen in these figures, FGF-2 injected into the S334ter rat retina substantially slows the progression of disease.

Figure 13 is a graph which plots Outer Nuclear Layer (ONL) thickness for FGF-2 subretinally injected, PBS subretinally injected, and an uninjected control.

Figure 14 is a bar graph which plots ONL thickness at p60.

Figures 15A, 15B and 15C are photographs of FGF-2 expressing cells stained with an anti-FGF-2 antibody.

Figures 16A and 16B are photographs which show gene delivery to cells in the ganglion cell layer following intraocular injection of recombinant rAAV-CMV-lacZ. a) superior quadrant of a retinal flat-mount processed for Blueo-Gal staining to visualize AAV-infected neurons. Notice the large number of axons converging at the optic nerve head (asterisk). b) Retinal radial section showing the AAV-mediated LacZ gene product in cells of the ganglion cell layer. A large number of these cells can be identified as RGCs because of the intense LacZ staining in axons projecting to the optic nerve head (asterisk). RPE: retinal pigment epithelium, PS: photoreceptor segments,

ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer, GCL: ganglion cell layer. Scale bars: a) 0.5 mm, b) 50 μ m.

Figure 17 is a graph which shows the time-course of AAV-mediated transgene expression in the ganglion cell layer of the adult rat retina. A recombinant AAV vector (rAAV-CMV-lacZ) was injected into the vitreous chamber of adult rats and 2, 4 and 8 weeks later, Lac-Z positive neurons in the ganglion cell layer (GCL) were counted in retinal flat-mounts. The values are the mean of 3-4 retinas per time point \pm standard deviation ($p < 0.001$).

Figures 18A and 18B are photographs which show the localization of the AAV-mediated LacZ gene product in retrogradely labeled RGCs. a) Retinal radial section showing LacZ immunopositive RGCs transduced with AAV (excitation 520-560, barrier 580, emission 580); b) Same section examined under a different fluorescent filter (excitation 355-425, barrier 460, emission 470) to visualize RGCs backlabeled with Fluorogold from the superior colliculus. Notice that the vast majority of LacZ immunopositive neurons are also labeled with Fluorogold. An exception, a LacZ positive cell that is not Fluorogold labeled, is shown (arrow), and could represent a displaced amacrine cell or RGC that did not incorporate the retrograde tracer. INL: inner nuclear layer, IPL: inner plexiform layer; GCL: ganglion cell layer. Scale bar: 10 μ m.

Figure 19 is a graph which quantifies Fluorogold- and LacZ-positive cells in the ganglion cell layer following intravitreal injection of rAAV-CMV-lacZ. The number of Fluorogold-positive cells (FG+) was compared to the number of cells that expressed both the Fluorogold and LacZ markers (FG+, LacZ+) and the number of cells expressing only the reporter gene (LacZ+). Values represent the mean of 4-5 retinal radial sections per animal ($n=4$) \pm standard deviation (S.D.) ($p < 0.001$).

Figure 20 is a photograph which shows the localization of the heparan sulfate (HS) proteoglycan receptor, the cellular receptor for AAV, in the intact adult rat retina. Retinal cryosection immunostained with a polyclonal antibody against the heparan sulfate (HepSS-1; diluted 1:200) followed by biotinylated anti-rabbit Fab fragment, avidin-biotin-peroxidase reagent (ABC Elite Vector Labs, Burlingame, CA). The section was reacted in a solution containing 0.05% diaminobenzidine tetrahydrochloride (DAB) and 0.06% hydrogen peroxide in PB (pH 7.4) for 5 min. Notice the strong labeling in RGCs in the ganglion cell layer (GCL). RPE: retinal pigment epithelium, PS: photoreceptor segments, ONL: outer nuclear layer, OPL: outer plexiform layer, INL: inner nuclear layer, IPL: inner plexiform layer. Scale bar: 50 μ m.

Figure 21 is a schematic illustration of pD10-VEGFuc.

Figure 22 is the nucleotide sequence of pD10-VEGF_{UC}.

Figure 23 is a bar graph which shows pD10-VEGF_{UC} rAAV virus infection of 293 cells.

Figure 24 is a three dimensional bar-graph which shows VEGF secretion by hfRPE after infection with VEGF AAV.

Figure 25 is a three dimensional bar-graph which shows VEGF secretion by hfRPE after infection with VEGF AV

Figure 26 is a three dimensional bar-graph which shows resistance of hfRPE after infection with VEGF AV.

Figure 27 is a schematic illustration of pD10-sFlt-1.

Figure 28 is the nucleotide sequence of pD10-sFlt-1.

Figure 29 is the nucleotide sequence of FGF-20.

Figure 30 is the nucleotide sequence of FGF-21.

Figure 31 is a schematic illustration of pD10K-FGF-2Sc.

Figure 32 is the nucleotide sequence of pD10K-FGF-2Sc.

Figure 33 is a graph which compares ONL thickness (um) after injection of various vectors into the eye.

DETAILED DESCRIPTION OF THE INVENTION

DEFINITIONS

Prior to setting forth the invention, it may be helpful to an understanding thereof to first set forth definitions of certain terms that will be used hereinafter.

"Gene delivery vector" refers to a construct which is capable of delivering, and, within preferred embodiments expressing, one or more gene(s) or sequence(s) of interest in a host cell. Representative examples of such vectors include viral vectors, nucleic acid expression vectors, naked DNA, and certain eukaryotic cells (e.g., producer cells).

"Recombinant adeno-associated virus vector" or "rAAV vector" refers to a gene delivery vector based upon an adeno-associated virus. The rAAV vectors, should contain 5' and 3' adeno-associated virus inverted terminal repeats (ITRs), and a transgene or gene of interest operatively linked to sequences which regulate its expression in a target cell. Within certain embodiments, the transgene may be operably linked to a heterologous promoter (such as CMV), or, an inducible promoter such as (tet). In addition, the rAAV vector may have a polyadenylation sequence.

"Neurotrophic Factor" or "NT" refers to proteins which are responsible for the development and maintenance of the nervous system. Representative examples

of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, and Fibroblast Growth Factors.

"Fibroblast Growth Factor" or "FGF" refers to a family of related proteins, the first of which was isolated from the pituitary gland (see Gospodarowicz, D., *Nature*, 249:123-127, 1974). From this original FGF (designated basic FGF) a family of related proteins, protein muteins, and protein analogs have been identified (see, e.g., U.S. Patent Nos. 4,444,760, 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226), all of which are generally referred to as Fibroblast Growth Factors within the context of the present invention.

"Anti-angiogenic Factor" refers to a factor or molecule which is able to inhibit the proliferation of vascular growth. A variety of assays may be utilized to assess the anti-angiogenic activity of a given molecule, including for example, the assay provided in Example 15, which measures HUVEC (human umbilical vein endothelial cell) proliferation. Representative examples of anti-angiogenic factors include for example, Angiostatin, 1,25-Di-hydroxy-vitamin D₃, Endostatin, IGF-1 receptor antagonists, Interferons alpha, beta and gamma, Interferon gamma-inducible protein IP-10, Interleukin 1 alpha and beta, Interleukin 12, 2-Methoxyestradiol, PEDF, Platelet factor 4, Prolactin (16kd fragment), Protamin, Retinoic acid, Thrombospondin-1 and 2, Tissue inhibitor of metalloproteinase-1 and -2, Transforming growth factor beta, soluble Tie-2 receptor, soluble Tie-2 receptor, soluble Flt-1 and Tumor necrosis factor - alpha.

"Diseases of the Eye" refers to a broad class of diseases wherein the functioning of the eye is affected due to damage or degeneration of the photoreceptors; ganglia or optic nerve; or neovascularization. Representative examples of such diseases include macular degeneration, diabetic retinopathies, inherited retinal degeneration such as retinitis pigmentosa, glaucoma, retinal detachment or injury and retinopathies (whether inherited, induced by surgery, trauma, a toxic compound or agent, or, photically).

As noted above, the present invention provides compositions and methods for treating, preventing, or, inhibiting diseases of the eye, comprising the general step of administering intraocularly a recombinant adeno-associated viral vector which directs the expression of one or more neurotrophic factors, such that the disease of the eye is treated or prevented. In order to further an understanding of the invention, a more detailed discussion is provided below regarding (A) gene delivery vectors; (B)

Neurotrophic Factors; (C) Anti-angiogenic factors; and (D) methods of administering the rAAVs in the treatment or prevention of diseases of the eye.

A. Gene Delivery Vectors

1. Construction of retroviral gene delivery vectors

5 Within one aspect of the present invention, retroviral gene delivery vectors are provided which are constructed to carry or express a selected gene(s) or sequence(s) of interest. Briefly, retroviral gene delivery vectors of the present invention may be readily constructed from a wide variety of retroviruses, including for example, B, C, and D type retroviruses as well as spumaviruses and lentiviruses (see RNA Tumor
10 Viruses, Second Edition, Cold Spring Harbor Laboratory, 1985). Such retroviruses may be readily obtained from depositories or collections such as the American Type Culture Collection ("ATCC"; Rockville, Maryland), or isolated from known sources using commonly available techniques.

 Any of the above retroviruses may be readily utilized in order to
15 assemble or construct retroviral gene delivery vectors given the disclosure provided herein, and standard recombinant techniques (*e.g.*, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Kunkel, *PNAS* 82:488, 1985). In addition, within certain embodiments of the invention, portions of the retroviral gene delivery vectors may be derived from different
20 retroviruses. For example, within one embodiment of the invention, retrovirus LTRs may be derived from a Murine Sarcoma Virus, a tRNA binding site from a Rous Sarcoma Virus, a packaging signal from a Murine Leukemia Virus, and an origin of second strand synthesis from an Avian Leukosis Virus.

 Within one aspect of the present invention, retrovector constructs are
25 provided comprising a 5' LTR, a tRNA binding site, a packaging signal, one or more heterologous sequences, an origin of second strand DNA synthesis and a 3' LTR, wherein the vector construct lacks *gag/pol* or *env* coding sequences.

 Other retroviral gene delivery vectors may likewise be utilized within the context of the present invention, including for example EP 0,415,731; WO 90/07936;
30 WO 91/0285, WO 9403622; WO 9325698; WO 9325234; U.S. Patent No. 5,219,740; WO 9311230; WO 9310218; Vile and Hart, *Cancer Res.* 53:3860-3864, 1993; Vile and Hart, *Cancer Res.* 53:962-967, 1993; Ram et al., *Cancer Res.* 53:83-88, 1993; Takamiya et al., *J. Neurosci. Res.* 33:493-503, 1992; Baba et al., *J. Neurosurg.* 79:729-735, 1993 (U.S. Patent No. 4,777,127, GB 2,200,651, EP 0,345,242 and WO91/02805).

Packaging cell lines suitable for use with the above described retrovector constructs may be readily prepared (see U.S. Serial No. 08/240,030, filed May 9, 1994; see also U.S. Serial No. 07/800,921, filed November 27, 1991), and utilized to create producer cell lines (also termed vector cell lines or "VCLs") for the production of recombinant vector particles.

2. Recombinant Adeno-Associated Virus Vectors

As noted above, a variety of rAAV vectors may be utilized to direct the expression of one or more desired neurotrophic factors. Briefly, the rAAV should be comprised of, in order, a 5' adeno-associated virus inverted terminal repeat, a transgene or gene of interest operatively linked to a sequence which regulates its expression in a target cell, and a 3' adeno-associated virus inverted terminal repeat. In addition, the rAAV vector may preferably have a polyadenylation sequence.

Generally, rAAV vectors should have one copy of the AAV ITR at each end of the transgene or gene of interest, in order to allow replication, packaging, and efficient integration into cell chromosomes. The ITR consists of nucleotides 1 to 145 at the 5' end of the AAV DNA genome, and nucleotides 4681 to 4536 (*i.e.*, the same sequence) at the 3' end of the AAV DNA genome. Preferably, the rAAV vector may also include at least 10 nucleotides following the end of the ITR (*i.e.*, a portion of the "D region").

Within preferred embodiments of the invention, the transgene sequence will be of about 2 to 5 kb in length (or alternatively, the transgene may additionally contain a "stuffer" or "filler" sequence to bring the total size of the nucleic acid sequence between the two ITRs to between 2 and 5 kb). Alternatively, the transgene may be composed of same heterologous sequence several times (*e.g.*, two nucleic acid molecules which encode FGF-2 separated by a ribosome readthrough, or alternatively, by an Internal Ribosome Entry Site or "IRES"), or several different heterologous sequences (*e.g.*, FGF-2 and FGF-5, separated by a ribosome readthrough or an IRES).

Recombinant AAV vectors of the present invention may be generated from a variety of adeno-associated viruses, including for example, serotypes 1 through 6. For example, ITRs from any AAV serotype are expected to have similar structures and functions with regard to replication, integration, excision and transcriptional mechanisms.

Within certain embodiments of the invention, expression of the transgene may be accomplished by a separate promoter (*e.g.*, a viral promoter). Representative examples of suitable promoters in this regard include a CMV promoter,

RSV promoter, SV40 promoter, or MoMLV promoter. Other promoters that may similarly be utilized within the context of the present invention include cell or tissue specific promoters (e.g., a rod, cone, or ganglia derived promoter), or inducible promoters. Representative examples of suitable inducible promoters include tetracycline-response promoters ("Tet", see, e.g., Gossen and Bujard, *Proc. Natl. Acad. Sci. USA.* 89:5547-5551, 1992; Gossen et al., *Science* 268, 1766-1769, 1995; Baron et al., *Nucl. Acids Res.* 25:2723-2729, 1997; Blau and Rossi, *Proc. Natl. Acad. Sci. USA.* 96:797-799, 1999; Bohl et al., *Blood* 92:1512-1517, 1998; and Haberman et al., *Gene Therapy* 5:1604-1611, 1998), the ecdysone system (see e.g., No et al., *Proc. Natl. Acad. Sci. USA.* 93:3346-3351, 1996), and other regulated promoters or promoter systems (see, e.g., Rivera et al., *Nat. Med.* 2:1028-1032, 1996;).

The rAAV vector may also contain additional sequences, for example from an adenovirus, which assist in effecting a desired function for the vector. Such sequences include, for example, those which assist in packaging the rAAV vector in adenovirus-associated virus particles.

Packaging cell lines suitable for producing adeno-associated viral vectors may be readily accomplished given readily available techniques (see e.g., U.S. Patent No. 5,872,005).

Particularly preferred methods for constructing and packaging rAAV vectors are described in more detail below in Examples 1, 2, 3, and 4.

3. Alphavirus delivery vectors

The present invention also provides a variety of Alphavirus vectors which may function as gene delivery vectors. For example, the Sindbis virus is the prototype member of the alphavirus genus of the togavirus family. The unsegmented genomic RNA (49S RNA) of Sindbis virus is approximately 11,703 nucleotides in length, contains a 5' cap and a 3' poly-adenylated tail, and displays positive polarity. Infectious enveloped Sindbis virus is produced by assembly of the viral nucleocapsid proteins onto the viral genomic RNA in the cytoplasm and budding through the cell membrane embedded with viral encoded glycoproteins. Entry of virus into cells is by endocytosis through clathrin coated pits, fusion of the viral membrane with the endosome, release of the nucleocapsid, and uncoating of the viral genome. During viral replication the genomic 49S RNA serves as template for synthesis of the complementary negative strand. This negative strand in turn serves as template for genomic RNA and an internally initiated 26S subgenomic RNA. The Sindbis viral nonstructural proteins are translated from the genomic RNA while structural proteins

are translated from the subgenomic 26S RNA. All viral genes are expressed as a polyprotein and processed into individual proteins by post translational proteolytic cleavage. The packaging sequence resides within the nonstructural coding region, therefore only the genomic 49S RNA is packaged into virions.

5 Several different Sindbis vector systems may be constructed and utilized within the present invention. Representative examples of such systems include those described within U.S. Patent Nos. 5,091,309 and 5,217,879, and PCT Publication No. WO 95/07994.

4. Other viral gene delivery vectors

10 In addition to retroviral vectors and alphavirus vectors, numerous other viral vectors systems may also be utilized as a gene delivery vector. Representative examples of such gene delivery vectors include viruses such as pox viruses, such as canary pox virus or vaccinia virus (Fisher-Hoch et al., *PNAS* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330 and 5,017,487; WO 89/01973); SV40 (Mulligan et al., *Nature* 277:108-114, 1979); influenza virus (Luytjes et al., *Cell* 59:1107-1113, 1989; McMichael et al., *N. Eng. J. Med.* 309:13-17, 1983; and Yap et al., *Nature* 273:238-239, 1978); herpes (Kit, *Adv. Exp. Med. Biol.* 215:219-236, 1989; U.S. Patent No. 5,288,641); HIV (Poznansky, *J. Virol.* 65:532-536, 1991); measles (EP 0 440,219); Semliki Forest Virus, and coronavirus, as well as other viral systems (e.g., EP 0,440,219; WO 92/06693; U.S. Patent No. 5,166,057). In addition, viral carriers may be homologous, non-pathogenic(defective), replication competent virus (e.g., Overbaugh et al., *Science* 239:906-910,1988), and nevertheless induce cellular immune responses, including CTL.

25 5. Non-viral gene delivery vectors

 In addition to the above viral-based vectors, numerous non-viral gene delivery vectors may likewise be utilized within the context of the present invention. Representative examples of such gene delivery vectors include direct delivery of nucleic acid expression vectors, naked DNA alone (WO 90/11092), polycation condensed DNA
30 linked or unlinked to killed adenovirus (Curiel et al., *Hum. Gene Ther.* 3:147-154, 1992), DNA ligand linked to a ligand with or without one of the high affinity pairs described above (Wu et al., *J. of Biol. Chem* 264:16985-16987, 1989), nucleic acid containing liposomes (e.g., WO 95/24929 and WO 95/12387) and certain eukaryotic

cells (*e.g.*, producer cells - see U.S. Serial No. 08/240,030, filed May 9, 1994, and U.S. Serial No. 07/800,921).

B. Neurotrophic Factors

As noted above, the term neurotrophic factor refers to proteins which are responsible for the development and maintenance of the nervous system. Representative examples of neurotrophic factors include NGF, BDNF, CNTF, NT-3, NT-4, and Fibroblast Growth Factors.

Fibroblast Growth Factor refers to a family of related proteins, the first of which was isolated from the pituitary gland (see Gospodarowicz, D., *Nature*, 249:123-127, 1974). From this original FGF (designated basic FGF) a family of related proteins, protein muteins, and protein analogs have been identified (see, *e.g.*, U.S. Patent Nos. 4,444,760, 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226; see generally Baird and Gospodarowicz, *D. Ann N.Y. Acad. Sci.* 638:1, 1991. The first two members of the family to be identified were acidic fibroblast growth factor (aFGF/FGF-1) and basic fibroblast growth factor (bFGF/FGF-2). Additional members of the FGF family include: i-nt-2/FGF-3, (Smith et al., *EMBO J.* 7: 1013, 1988); FGF-4 (Delli-Bovi et al., *Cell* 50: 729, 1987); FGF-6 (Marics et al., *Oncogene* 4: 335 (1989); keratinocyte growth factor/FGF-7, (Finch et al., *Science* 245: 752, 1989); FGF-8 (Tanaka et al., *Proc. Natl. Acad. Sci. USA* 89: 8928, 1992); and FGF-9 (Miyamoto et al., *Mol. Cell Biol.* 13: 4251, 1993).

FGF-5 was originally isolated as an oncogene. See Goldfarb et al. US Patent Nos. 5,155,217 and 5,238,916, Zhan et al. "Human Oncogene Detected by a Defined Medium Culture Assay" (*Oncogene* 1:369-376, 1987), Zhan et al. "The Human FGF-5 Oncogene Encodes a Novel Protein Related to Fibroblastic Growth Factors" (*Molecular and Cellular Biology* 8:3487-3495, 1988), and Bates et al. "Biosynthesis of Human Fibroblast Growth Factor 5": (*Molecular and Cellular Biology* 11:1840-1845, 1991).

Other FGFs include those disclosed in U.S. Patent Nos. 4,444,760, 5,155,214, 5,371,206, 5,464,774, 5,464,943, 5,604,293, 5,731,170, 5,750,365, 5,851,990, 5,852,177, 5,859,208, and 5,872,226, 5,852,177, and 5,872,226, as well as FGF-20 (U.S. Provisional Application No. 60/161,162) and FGF-21 (U.S. Provisional Application No. 60/166,540).

C. Anti-Angiogenic Factors

A wide variety of anti-angiogenic factors may also be expressed from the gene delivery vectors of the present invention, including for example, Angiostatin (O'Reilly et al., *Cell* 79:315-328, 1994; O'Reilly et al., *Nat. Med.* 2:689-92, 1996; Sim et al., *Cancer Res.* 57:1329-34, 1997), 1,25-Di-hydroxy-vitamin D₃ (Shibuya et al., *Oncogene* 5:519-24, 1990; Oikawa et al., *Eur. J. Pharmacol.* 178:247-50, 1990; and 182:616, 1990), Endostatin (O'Reilly et al., *Cell* 88:277-85, 1997), Interferons alpha and beta (Sidky et al., *Cancer Res.* 47:5155-61, 1987; Singh et al., *Proc. Natl. Acad. Sci. USA* 92:4562-6, 1995), Interferon gamma (Friesel et al., *J. Cell. Biol.* 104:689-96, 1987), IGF-1 receptor antagonists, Interferon gamma-inducible protein IP-10 (Arenberg et al., *J. Exp. Med.* 1996;184:981-92; Strieter et al., *J. Leukoc. Biol.* 1995;57:752-62; Angiolillo et al., *J. Exp. Med.* 182:155-62, 1995), Interleukin 1alpha and beta (Cozzolino et al., *Proc. Natl. Acad. Sci. USA* 87:6487-91, 1990), Interleukin 12 (Kerbel and Hawley, *J. Natl. Cancer Inst.* 87:557-9, 1995; Majewski et al., *J. Invest. Dermatol.* 106:1114-8, 1996; Voest et al., *J. Natl. Cancer Inst.* 87:581-6, 1995), 2-Methoxyestradiol (Fotsis et al., *Nature* 368:237-9, 1994), PEDF, Platelet factor 4 (Taylor and Folkman, *Nature* 297:307-12, 1982; Gengrinovitch et al., *J. Biol. Chem.* 270:15059-65, 1995), Prolactin (16kd fragment) (Clapp et al., *Endocrinology* 133:1292-9, 1993; Ferrara, *Endocrinology* 129:896-900, 1991), Protamin, Retinoic acid (Lingen et al., *Lab. Invest.* 74:476-83, 1996), Thrombospondin-1 and 2 (Lawler, *Blood*, 67:1197-209, 1986; Raugi and Lovett, *Am. J. Pathol.* 129:364-72, 1987; Volpert et al., *Biochem. Biophys. Res. Commun.* 217:326-32, 1995), Tissue inhibitor of metalloproteinase-1 and -2 (Moses and Langer, *J. Cell Biochem.* 47:230-5, 1991; Ray and Stetler-Stevenson, *Eur. Respir. J.* 7:2062-72, 1994), Transforming growth factor beta (Ray-Chaudhury, *J. Cell. Biochem.* 47:224-9, 1991; Roberts et al., *Proc. Natl. Acad. Sci. USA* 83:4167-71, 1986), and Tumor necrosis factor - alpha (Frater-Schroeder et al., *Proc. Natl. Acad. Sci. USA* 84:5277-81, 1987; Leibovich et al., *Nature* 329:630-2, 1987).

Other anti-angiogenic factors that can be utilized within the context of the present invention include VEGF antagonists such as soluble Flt-1 (Kendall and Thomas, *PNAS* 90: 10705, 1993), and Ang-1 antagonists such as soluble Tie-2 receptor (Thurston et al., *Science* 286:2511, 1999; see also, generally Aiello et al., *PNAS* 92:10457, 1995; Robinson et al., *PNAS* 93:4851, 1996; Seo et al., *Am. J. Pathol.* 154:1743, 1999).

The ability of a given molecule to be "anti-angiogenic" can be readily assessed utilizing a variety of assays, including for example, the HUVEC assay provided in Example 15.

D. Method for Treating and/or Preventing Diseases of the Eye, and Pharmaceutical Compositions

As noted above, the present invention provides methods which generally comprise the step of intraocularly administering a gene delivery vector which directs the expression of one or more neurotrophic factor to the eye, or an anti-angiogenic factor to the eye in order to treat, prevent, or inhibit the progression of an eye disease. As utilized herein, it should be understood that the terms "treated, prevented, or, inhibited" refers to the alteration of a disease course or progress in a statistically significant manner. Determination of whether a disease course has been altered may be readily assessed in a variety of model systems, discussed in more detail below, which analyze the ability of a gene delivery vector to delay, prevent or rescue photoreceptors, as well as other retinal cells, from cell death.

1. Diseases of the eye

A wide variety of diseases of the eye may be treated given the teachings provided herein. For example, within one embodiment of the invention gene delivery vectors are administered to a patient intraocularly in order to treat or prevent macular degeneration. Briefly, the leading cause of visual loss in the elderly is macular degeneration (MD), which has an increasingly important social and economic impact in the United States. As the size of the elderly population increases in this country, age related macular degeneration (AMD) will become a more prevalent cause of blindness than both diabetic retinopathy and glaucoma combined. Although laser treatment has been shown to reduce the risk of extensive macular scarring from the "wet" or neovascular form of the disease, there are currently no effective treatments for the vast majority of patients with MD.

Within another embodiment, gene delivery vectors can be administered to a patient intraocularly in order to treat or prevent an inherited retinal degeneration. One of the most common inherited retinal degenerations is retinitis pigmentosa (RP), which results in the destruction of photoreceptor cells, and the RPE. Other inherited conditions include Bardet-Biedl syndrome (autosomal recessive); Congenital amaurosis (autosomal recessive); Cone or cone-rod dystrophy (autosomal dominant and X-linked forms); Congenital stationary night blindness (autosomal dominant, autosomal recessive and X-linked forms); Macular degeneration (autosomal dominant and autosomal recessive forms); Optic atrophy, autosomal dominant and X-linked forms); Retinitis pigmentosa (autosomal dominant, autosomal recessive and X-linked forms); Syndromic or systemic retinopathy (autosomal dominant, autosomal recessive and X-linked forms);

and Usher syndrome (autosomal recessive). This group of debilitating conditions affects approximately 100,000 people in the United States alone.

As noted above, within other aspects of the invention, gene delivery vectors which direct the expression of a neurotrophic growth factor can be administered to a patient intraocularly in order to treat or prevent glaucoma. Briefly, glaucoma is not a uniform disease but rather a heterogeneous group of disorders that share a distinct type of optic nerve damage that leads to loss of visual function. The disease is manifest as a progressive optic neuropathy that, if left untreated leads to blindness. It is estimated that as many as 3 million Americans have glaucoma and, of these, as many as 120,000 are blind as a result. Furthermore, it is the number one cause of blindness in African-Americans. Its most prevalent form, primary open-angle glaucoma, can be insidious. This form usually begins in midlife and progresses slowly but relentlessly. If detected early, disease progression can frequently be arrested or slowed with medical and surgical treatment. Representative factors that may be expressed from the vectors of the present invention to treat glaucoma include neurotrophic growth factors such as FGF-2, 5, 18, 20, and, 21.

Within yet other embodiments gene delivery vectors can be administered to a patient intraocularly in order to treat or prevent injuries to the retina, including retinal detachment, photic retinopathies, surgery-induced retinopathies, toxic retinopathies, retinopathies due to trauma or penetrating lesions of the eye.

As noted above, the present invention also provides methods of treating, preventing, or, inhibiting neovascular disease of the eye, comprising the step of administering to a patient a gene delivery vector which directs the expression of an anti-angiogenic factor. Representative examples of neovascular diseases include diabetic retinopathy, ARMD (wet form), and retinopathy of prematurity. Briefly, choroidal neovascularization is a hallmark of exudative or wet Age-related Macular Degeneration (AMD), the leading cause of blindness in the elderly population. Retinal neovascularization occurs in diseases such as diabetic retinopathy and retinopathy of prematurity (ROP), the most common cause of blindness in the young.

Particularly preferred vectors for the treatment, prevention, or, inhibition of neovascular diseases of the eye direct the expression of an anti-angiogenic factor such as, for example, soluble tie-2 receptor or soluble Flt-1.

2. Animal Models

In order to assess the ability of a selected gene therapy vector to be effective for treating diseases of the eye which involve neovascularization, a novel

model for neovascularization (either choroidal or subretinal) can be generated by subretinal injection of a recombinant virus (rAV or rAAV) containing an angiogenic transgene such as VEGF and/or angiopoietin. The extent and duration of neovascularization induced by rAAV and rAV vectors containing an angiogenic transgene such as VEGF can be determined using fundus photography, fluorescein angiography and histochemistry.

To assess the ability of anti-angiogenic molecules to prevent neovascularization in the model described above, a D10- sFlt-1 rAAV (or other gene delivery vector which directs the expression of an anti-angiogenic factor) is intraocularly injected, either by subretinal or intravitreal routes of injection. Generally, subretinal injection of the gene delivery vector may be utilized to achieve delivery to both the choroidal and inner retinal vasculature. Intravitreal injection can be utilized to infect Muller cells and retinal ganglion cells (RGCs), which deliver anti-angiogenic protein to the retinal vasculature. Muller cells span the retina and would secrete the therapeutic protein into the subretinal space.

Such injections may be accomplished either prior to, simultaneous with, or subsequent to administration of an angiogenic factor or gene delivery vector which expresses an angiogenic factor. After an appropriate time interval, inhibition of neovascularization can be determined using fundus photography, fluorescein angiography and/or histochemistry.

While there are many animal models of retinal neovascularization such as oxygen-induced ischemic retinopathy (Aiello et al., PNAS 93: 4881, 1996.) and the VEGF transgenic mouse (Okamoto et al., Am. J. Pathol. 151: 281, 1997), there are fewer models of choroidal neovascularization (e.g., laser photocoagulation as described by Murata et al., IOVS 39: 2474, 1998). Subretinal neovascularization from the retinal rather than choroidal blood supply is also observed in VEGF transgenic animals (Okamoto et al., Am. J. Pathol. 151: 281, 1997). Hypoxic stimulation of VEGF expression is known to correlate with neovascularization in human ocular disease.

The pathologic hallmark of glaucomatous optic neuropathy is the selective death of retinal ganglion cells (RGCs) (Nickells, R.W., *J. Glaucoma* 5:345-356, 1996; Levin, L.A. and Louhab, A., *Arch. Ophthalmol.* 114:488-491, 1996.; Kerrigan, L.A., Zack, D.J., Quigley, H.A., Smith, S.D. and Pease, M.E., *Arch. Ophthalmol.* 115:1031-1035, 1997). Recent studies indicate that RGCs die with characteristics of apoptosis after injury to the axons of adult RGCs such as axotomy of the optic nerve (ON), and in glaucoma and anterior ischemic optic neuropathy in

humans (Nickells, 1996). Thus, damage to the optic nerve by axotomy is used by many researchers as a model for selective apoptotic cell death of adult RGCs.

The loss of RGCs caused by ON transection in adult mammals varies from 50% to more than 90% depending on the techniques used to identify RGCs, the proximity of the lesion to the eye, and the age and species of the animal. For example, in a study in adult rats, in which retrogradely transported tracers were used to distinguish RGCs from displaced amacrine cells (Villegas-Pérez, M.P., Vidal-Sanz, M., Bray, G.M. and Aguayo, A.J., *J. Neurosci.* 8:265-280, 1988). ON transection near the eye (0.5-1 mm) leads to the loss of more than 90% of the RGCs by 2 weeks. In contrast, in adult animals in which the ON was cut nearly 10 mm from the eye, 54% of RGCs survived by 3 months (Richardson, P.M., Issa, V.M.K. and Shemie, S., *J. Neurocytol.* 11:949-966, 1982.).

Briefly, the posterior pole of the left eye and the origin of the optic nerve (ON) are exposed through a superior temporal intraorbital approach. A longitudinal excision of the ON dural sheath is performed. The ON is then gently separated from the dorsal aspect of this sheath and completely transected within the orbit, within 1 mm of the optic disc. Care is taken to avoid damage to the ophthalmic artery, which is located on the inferomedial dural sheath of the ON.

RGC survival and death following gene delivery can also be examined using two alternative models of ON injury: 1) ON crush; and (2) increased intraocular pressure. In the first model the ON is exposed, and then clamped at a distance of about one millimeter from the posterior pole using a pair of calibrated forceps as previously described (Li et al., *Invest. Ophthalmol. Vis. Sci.* 40:1004, 1999). In the second model, chronic moderately elevated intraocular pressure can be produced unilaterally by cauterization of three episcleral vessels as described by Neufeld et al. in *PNAS* 17:9944, 1999).

A variety of animal models can be utilized for photoreceptor degeneration, including the RCS rat model, P23H transgenic rat model, the rd mouse, and the S334ter transgenic rat model.

Briefly, in the S334ter transgenic rat model, a mutation occurs resulting in the truncation of the C-terminal 15 amino acid residues of rhodopsin (a seven-transmembrane protein found in photoreceptor outer segments, which acts as a photopigment). The S334ter mutation is similar to rhodopsin mutations found in a subset of patients with retinitis pigmentosa (RP). RP is a heterogeneous group of inherited retinal disorders in which individuals experience varying rates of vision loss due to photoreceptor degeneration. IN many RP patients, photoreceptor cell death

progresses to blindness. Transgenic S334ter rats are born with normal number of photoreceptors. The mutant rhodopsin gene begins expression at postnatal day 5 in the rat, and photoreceptor cell death begins at postnatal day 10-15. In transgenic line S334ter-3, approximately 70% of the outer nuclear layer has degenerated by day 60 in the absence of any therapeutic intervention. The retinal degeneration in this model is consistent from animal to animal and follows a predictable and reproducible rate. This provides an assay for therapeutic effect by morphological examination of the thickness of the photoreceptor nuclear layer and comparison of the treated eye to the untreated (contralateral) eye in the same individual animal.

S334ter rats are utilized as a model for RP as follows. Briefly, S334ter transgenic rats are euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 % glutaraldehyde). Eyes are removed and embedded in epoxy resin, and 1 μ m thick histological sections are made along the vertical meridian. Tissue sections are aligned so that the ROS and Müller cell processes crossing the inner plexiform layer are continuous throughout the plane of section to assure that the sections are not oblique, and the thickness of the ONL and lengths of RIS and ROS are measured. These retinal thickness measurements are plotted and establish the baseline retinal degeneration rates for the animal model. The assessment of retinal thickness is as follows: briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. These data were either averaged to provide a single value for the retina, or plotted as a distribution of thickness or length across the retina. The greatest 3 contiguous values for ONL thickness in each retina is also compared in order to determine if any region of retina (e.g., nearest the injection site) showed proportionally greater rescue; although most of these values were slightly greater than the overall mean of all 54 values, they were no different from control values than the overall mean. Thus, the overall mean was used in the data cited, since it was based on a much larger number of measurements.

One particularly preferred line of transgenic rats, TgN(s334ter) line 4 (abbreviated s334ter 4) can be utilized for *in vivo* experiments. Briefly, in this rat model expression of the mutated opsin transgene begins at postnatal day P5 in these rats, leading to a gradual death of photoreceptor cells. These rats develop an anatomically normal retina up to P15, with the exception of a slightly increased number of pyknotic photoreceptor nuclei in the outer nuclear layer (ONL) than in non-transgenic control rats. In this animal model, the rate of photoreceptor cell death is approximately linear until P60, resulting in loss of 40-60% of the photoreceptors.

After P60, the rate of cell loss decreases, until by one year the retinas have less than a single row of photoreceptor nuclei remaining.

3. Methods of Administration

Gene delivery vectors of the present invention may be administered
5 intraocularly to a variety of locations depending on the type of disease to be treated, prevented, or, inhibited, and the extent of disease. Examples of suitable locations include the retina (*e.g.*, for retinal diseases), the vitreous, or other locations in or adjacent to the eye.

Briefly, the human retina is organized in a fairly exact mosaic. In the
10 fovea, the mosaic is a hexagonal packing of cones. Outside the fovea, the rods break up the close hexagonal packing of the cones but still allow an organized architecture with cones rather evenly spaced surrounded by rings of rods. Thus in terms of densities of the different photoreceptor populations in the human retina, it is clear that the cone density is highest in the foveal pit and falls rapidly outside the fovea to a fairly even
15 density into the peripheral retina (see Osterberg, G. (1935) Topography of the layer of rods and cones in the human retina. *Acta Ophthal.* (suppl.) 6, 1-103; *see also* Curcio, C. A., Sloan, K. R., Packer, O., Hendrickson, A. E. and Kalina, R. E. (1987) Distribution of cones in human and monkey retina: individual variability and radial asymmetry. *Science* 236, 579-582).

20 Access to desired portions of the retina, or to other parts of the eye may be readily accomplished by one of skill in the art (*see*, generally Medical and Surgical Retina: Advances, Controversies, and Management, Hilel Lewis, Stephen J. Ryan, Eds., medical illustrator, Timothy C. Hengst. St. Louis: Mosby, c1994. xix, 534; *see also* Retina, Stephen J. Ryan, editor in chief, 2nd ed., St. Louis, Mo.: Mosby, c1994. 3 v.
25 (xxix, 2559 p.).

The amount of the specific viral vector applied to the retina is uniformly quite small as the eye is a relatively contained structure and the agent is injected directly into it. The amount of vector that needs to be injected is determined by the intraocular location of the chosen cells targeted for treatment. The cell type to be transduced will
30 be determined by the particular disease entity that is to be treated.

For example, a single 20-microliter volume (of 10^{13} physical particle titer/ml rAAV) may be used in a subretinal injection to treat the macula and fovea. A larger injection of 50 to 100 microliters may be used to deliver the rAAV to a substantial fraction of the retinal area, perhaps to the entire retina depending upon the
35 extent of lateral spread of the particles.

A 100-ul injection will provide several million active rAAV particles into the subretinal space. This calculation is based upon a titer of 10^{13} physical particles per milliliter. Of this titer, it is estimated that 1/1000 to 1/10,000 of the AAV particles are infectious. The retinal anatomy constrains the injection volume possible in the subretinal space (SRS). Assuming an injection maximum of 100 microliters, this would provide an infectious titer of 10^8 to 10^9 rAAV in the SRS. This would have the potential of infecting all of the $\sim 150 \times 10^6$ photoreceptors in the entire human retina with a single injection.

Smaller injection volumes focally applied to the fovea or macula may adequately transfect the entire region affected by the disease in the case of macular degeneration or other regional retinopathies.

Gene delivery vectors can alternately be delivered to the eye by intraocular injection into the vitreous. In this application, the primary target cells to be transduced are the retinal ganglion cells, which are the retinal cells primarily affected in glaucoma. In this application, the injection volume of the gene delivery vector could be substantially larger, as the volume is not constrained by the anatomy of the subretinal space. Acceptable dosages in this instance can range from 25 ul to 1000 ul.

4. Assays

A wide variety of assays may be utilized in order to determine appropriate dosages for administration, or to assess the ability of a gene delivery vector to treat or prevent a particular disease. Certain of these assays are discussed in more detail below.

a. Electroretinographic analysis

Electroretinographic analysis can be utilized to assess the effect of gene delivery administration into the retina. Briefly, rats are dark adapted overnight and then in dim red light, then anesthetized with intramuscular injections of xylazine (13 mg/kg) and ketamine (87 mg/kg). Full-field scotopic ERGs are elicited with 10- μ sec flashes of white light and responses were recorded using a UTAS-E 2000 Visual Electrodiagnostic System (LKC Technologies, Inc., Gaithersburg, MD). The corneas of the rats are the anesthetized with a drop of 0.5% proparacaine hydrochloride, and the pupils dilated with 1% atropine and 2.5% phenylephrine hydrochloride. Small contact lenses with gold wire loops are placed on both corneas with a drop of 2.5% methylcellulose to maintain corneal hydration. A silver wire reference electrode is placed subcutaneously between the eyes and a ground electrode is placed subcutaneously in the hind leg.

Stimuli are presented at intensities of -1.1, 0.9 and 1.9 log cd m⁻² at 10-second, 30-second and 1-minute intervals, respectively. Responses are amplified at a gain of 4,000, filtered between 0.3 to 500 Hz and digitized at a rate of 2,000 Hz on 2 channels. Three responses are averaged at each intensity. The a-waves are measured from the baseline to the peak in the cornea-negative direction, and b-waves are measured from the cornea-negative peak to the major cornea-positive peak. For quantitative comparison of differences between the two eyes of rats, the values from all the stimulus intensities are averaged for a given animal.

b. Retinal tissue analysis

As described in more detail above and below, retinal tissue analysis can also be utilized to assess the effect of gene delivery administration into the retina.

5. Pharmaceutical Compositions

Gene delivery vectors may be prepared as a pharmaceutical product suitable for direct administration. Within preferred embodiments, the vector should be admixed with a pharmaceutically acceptable carrier for intraocular administration. Examples of suitable carriers are saline or phosphate buffered saline.

DEPOSIT INFORMATION

The following material was deposited with the American Type Culture Collection:

<u>Name</u>	<u>Deposit Date</u>	<u>Accession No.</u>
PKm201bFGF-2	3/11/99	#207160
PD10-Kan-FGF-2-Sc		

The above material was deposited by Chiron Corporation with the American Type Culture Collection (ATCC), 10801 University Blvd., Manassas, VA 20110-2209, telephone 703-365-2700. This deposit will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for purposes of Patent Procedure. The deposit will be maintained for a period of 30 years following issuance of this patent, or for the enforceable life of the patent, whichever is greater. Upon issuance of the patent, the deposits will be available to the public from the ATCC without restriction.

This deposit is provided merely as a convenience to those of skill in the art, and is not an admission that a deposit is required under 35 U.S.C. § 112. The nucleic acid sequence of this deposit, as well as the amino acid sequence of the polypeptide encoded thereby, are incorporated herein by reference and should be referred to in the event of an error in the sequence described herein. A license may be required to make, use, or sell the deposited materials, and no such license is granted hereby.

The following examples are offered by way of illustration, and not by way of limitation.

EXAMPLES

EXAMPLE 1

CONSTRUCTION OF A RAAV VECTOR EXPRESSING FGF-2

5 pKm201CMV is an AAV cloning vector in which an expression cassette, consisting of a CMV immediate early promoter/enhancer and a bovine growth hormone (BGH) polyadenylation site, is flanked by inverted terminal repeat (ITR) sequences from AAV-2. Briefly, pKm201CMV was derived from pKm201, a modified AAV vector plasmid in which the ampicillin resistance gene of pEMBL-AAV-ITR (see
10 Srivastava, (1989) *Proc. Natl. Acad. Sci. USA* 86:8078-8082) had been replaced with the gene for kanamycin resistance. The expression cassette from pCMVlink, a derivative of pCMV6c (see Chapman, *Nucleic Acids Res.* 19:193-198 (1991)) in which the BGH poly A site has been substituted for the SV40 terminator, was inserted between the ITRs of pKm201 to generate pKm201CMV.

15 pKm201bFGF-2 was constructed by cloning the following, in order, into the multiple cloning site of pKm201CMV: the encephalomyocarditis virus (EMCV) internal ribosome entry site (IRES), the bovine FGF-2 cDNA, and the human growth hormone polyadenylation sequence. The cDNA for FGF-2 has two mutations that change amino acid 121 from serine to threonine and amino acid 137 from proline to
20 serine. The DNA sequence of pKm201bFGF-2 is shown in Figure 2 and the plasmid has been deposited with the American Type Culture Collection (ATCC).

rAAV vector particles were produced by a triple transfection protocol (*Nucleic Acids Res.* 24:596-601, 1996; *J. Exp. Med.* 179:1867-1875, 1994). Briefly, human embryonic kidney 293 cells, grown to 50% confluence in a 10 layer Nunclon
25 cell factory (Nalge Nunc, Int., Naperville, IL), were co-transfected with 400 µg of helper plasmid pKSrep/cap (*Hum. Gene Ther.* 9:477-485, 1998) 400 µg of vector plasmid, and 800 µg of adenovirus plasmid pBHG10 (Microbix Biosystems, Inc., Toronto, Ontario) using the calcium phosphate co-precipitation method. Forty-eight hours after co-transfection, media was replaced with IMDM + 10% FBS containing
30 adenovirus type 5 dl312 at a multiplicity of infection (MOI) of 2. Seventy-two hours after infection cells were harvested and resuspended in HEPES buffer (2.5 ml per dish) and lysed by three cycles of freezing and thawing. Cell debris was removed by centrifugation at 12,000X g for 20 min. Packaged rAAV was purified from adenovirus by two rounds of cesium chloride equilibrium density gradient centrifugation. Residual
35 adenovirus contamination was inactivated by heating at 56°C for 45 min. Though three

plasmids were used in the production of rAAV vector in this example, it is possible to combine the rAAV vector construct and the AAV helper gene construct on one plasmid. This would allow rAAV to be produced by transfecting 293 cells with two plasmids. Alternatively, one could add the adenovirus helper genes to this plasmid to make a
5 single plasmid containing all that is required to make rAAV particles.

To estimate total number of rAAV particles, the virus stock was treated with DNase I, and encapsidated DNA was extracted with phenol-chloroform, and precipitated with ethanol. DNA dot blot analysis against a known standard was used to determine titer (*Blood* 76:1997-2000, 1990).

10 To assay for adenovirus contamination, 293 cells were infected with 10 μ l of purified rAAV stock and followed for any signs of cytopathic effect. All stocks were negative for adenovirus contamination (level of detection greater than or equal to 100 PFU/ml).

To assay for wild type AAV, 293 cells were co-infected with serial
15 dilutions of rAAV stocks and adenovirus dl312 at a MOI of 2. Three days later the cells were harvested, lysed by three cycles of freezing/thawing, and centrifuged to remove cell debris. The supernatant was heat inactivated (56°C for 10 min) and fresh plates of 293 cells (6×10^6) were infected in the presence of adenovirus dl312 at a MOI of 2. Forty-eight hours after infection, low molecular-weight DNA was isolated (*J. Mol. Biol.*
20 26:365-369, 1967) subjected to agarose gel electrophoresis, and transferred to a nylon membrane. The membrane was hybridized with a biotinylated oligonucleotide probe specific for the AAV capsid region. The wild type AAV titer was defined as the highest dilution of rAAV vector stock demonstrating a positive hybridization signal. The rAAV preparations contained less than 1 wild type AAV genome per 10^9 rAAV
25 genomes.

EXAMPLE 2

INFECTION OF CELLS WITH RAAV-CMV-FGF-2 RESULTS IN THE EXPRESSION OF FGF-2

293 cells were plated the day before infection at 5×10^5 cells/well in 6-
30 well plates and were infected with rAAV-CMV-bFGF-2 virus, prepared as described above in Example 1, at different multiplicities of infection (MOI) with and without etoposide (3 μ M). Etoposide is a topoisomerase inhibitor which has been shown to increase transduction efficiency of rAAV vectors (*Proc. Natl. Acad. Sci. USA*, 92:5719-5723, 1995). Forty-eight hours after infection, culture supernatant was collected and
35 cells were lysed in 0.5 mL 1x lysis buffer (100 mM NaCl, 20 mM Tris pH 7.5, 1 mM

EDTA, 0.5% NP40, and 0.5% deoxycholate). FGF-2 in the supernatants and lysates was assayed by ELISA (cat. # DFB00, R & D Systems, Minneapolis, MN) following manufacturer's instructions. The results are shown below in Table 1.

TABLE 1**5 FGF-2 PRODUCTION IN 293 CELLS FOLLOWING INFECTION WITH RAAV-FGF-2****Culture Medium Supernatant (1.5 ml)**

sample	infection MOI	Etoposide	FGF2 protein
1	0	-	<5 pg/ml
2	2X10 ⁵	-	<5 pg/ml
3	2X10 ⁴	-	<5 pg/ml
4	2X10 ³	-	<5 pg/ml
1	0	+	<5 pg/ml
2	2X10 ⁵	+	106 pg/ml \approx 300pg/24h/10 ⁶ cells
3	2X10 ⁴	+	<5 pg/ml
4	2X10 ³	+	<5 pg/ml

Cell Lysate (0.5 ml)

sample	infection MOI	Etoposide	FGF2 protein
1	0	-	8.95 ng/ml
2	2X10 ⁵	-	114. ng/ml
3	2X10 ⁴	-	18.8 ng/ml
4	2X10 ³	-	11.3 ng/ml
1	0	+	5.05 ng/ml
2	2X10 ⁵	+	296. ng/ml \approx 300ng/24h/10 ⁶ cells
3	2X10 ⁴	+	48.0 ng/ml
4	2X10 ³	+	13.2 ng/ml

EXAMPLE 3**10 CONSTRUCTION OF RAAV VECTORS****A. Construction of pD10-bFGF-2**

The pD10 AAV vector is constructed by replacing the AAV gene encoding sequences of pD-10 (see Wang, X. et al. *J. Virol.* 71:3077 (1997), with the CMV promoter, multiple cloning site, and BGH polyadenylation sequences from

15 pKm201CMV. Briefly, oligonucleotides 5'-ggtatttaa acttgccgcc gcggaattc gactctagc

c-3' (SEQ I.D. No. ____) and 5'-gctgcccggg acttgctagc tggatgatcc tccagcgagg ggatctcatg -3' (SEQ I.D. No. ____) are used to amplify the CMV expression cassette from pKm201CMV. The product of this PCR amplification is digested with SmaI and DraI and cloned into pD-10 digested with EcoRV. This new vector is named pD10-CMV.

- 5 To construct pD10-bFGF-2, the synthetic gene for bovine FGF-2 (see US Patent 5,464,774 for sequence) is digested with EcoRI and Sall, treated with T4 polymerase to blunt the ends, and then cloned into the StuI site of pD10-CMV. The synthetic gene described above encodes the mature, processed form of bovine FGF-2.

B. Construction of a rAAV Vector Expressing FGF-2-Sc.

- 10 pD10-K-FGF-2-Sc (see Figure 31) was constructed by cloning the FGF-2 full length humanized bovine cDNA obtained from Scios, into the pD10 vector backbone containing the kanamycin (Kan) resistance gene. This cDNA contains the mutations at amino acid positions 121 and 137 described in example 1. Briefly, the FGF-2-Sc cDNA was digested from the parent plasmid with the enzyme NdeI, the ends
15 blunted with T4 DNA polymerase, cut with the restriction enzyme HindIII, and cloned into the pD10-CMV vector which had been digested with the enzymes StuI and HindIII. The nucleotide sequence of pD10-K-FGF-2-Sc is illustrated in Figure 32.

C. Infection of Cells with rAAV-FGF-2-Sc Results in the Expression of FGF-2

- 20 293 cells were infected as in example 2, with the following modifications: 4 x 10⁵ cells/well were plated in a 12 well dish, and all wells contained 3 uM etoposide. Three different particle numbers of FGF-2 virus, and a negative control CMV-lacZ virus were used to infect the cells. 48 hours after infection, tissue culture media was collected and cells lysed in 100 ul lysis buffer containing Triton-X 100 and CompleteTM protein inhibitor cocktail (Boehringer Mannheim, Germany).
25 FGF-2 protein in the media and lysates was assayed by ELISA. The results are shown below in Table 2 below.

TABLE 2
FGF-2 PRODUCTION IN 293 CELLS FOLLOWING INFECTION WITH RAAV
D10-K-FGF-2-Sc

Vector	Viral Particles	Lysates(pg/mL)	Culture media (pg/mL)
D10-K-FGF-2-Sc	1 x 10e10	324492.919	438.621
D10-K-FGF-2-Sc	1 x 10e9	32876.106	46.984
D10-K-FGF-2-Sc	1 x 10e8	6950.039	14.649
CMV -lacZ	1 x 10e10	2327.527	17.096

EXAMPLE 4

5 CONSTRUCTION OF RAAV VECTORS WHICH EXPRESS FGF5 AND FGF18

A. Cloning FGF-5 into the pD10-CMV rAAV Vector.

The FGF-5 coding region (see U.S. Serial No. 08,602,147) was cloned into the rAAV pD10-CMV vector by digestion with the enzymes SacII and XmnI, resulting in an 814 bp fragment. This removed an ORF (ORF-1) upstream of and
10 overlapping with the FGF-5 coding region. The ends of the FGF-5 fragment were then blunted with T4 DNA polymerase, and it was cloned into the rAAV pD10-CMV vector linearized with StuI. This vector contains a 1353 bp insertion of a bacteriophage Phi X174 HaeIII fragment.

The pD10-CMV-FGF-5 vector is illustrated schematically in Figure 3.
15 In summary, this plasmid contains the CMV immediate/early enhancer + promoter, the CMV intron A, an FGF-5 coding region, the bovine growth hormone polyA site, and AAV ITR sequences. There is a 1353 bp insertion of PhiX 174 bacteriophage DNA cloned into the NotI site between one ITR and the CMV immediate early enhancer + promoter region.

20 B. Packaging and Functional Analysis of FGF-5 rAAV.

rAAV virus was packaged using a triple transfection method as described in Example 1. However, rather than cesium chloride equilibrium density gradient centrifugation, heparin sulfate column chromatography is utilized. More specifically, a cell pellet is resuspended in TNM buffer: 20mM Tris pH 8.0, 150mM

NaCl, 2mM MgCl₂. Deoxycholic Acid is added to 0.5% to lyse the cells. 50 U/ml Benzonase is added and the lysed cells are incubated at 37 degrees to digest any nucleic acids. The cell debris is pelleted and the supernatant is filtered through a 0.45um filter and then a 0.22um filter. The virus is then loaded onto a 1.5ml Heparin sulfate column using the Biocad HPLC. The column is then washed with 20mM Tris pH 8.0, 100mM NaCl. The rAAV particles are eluted with a gradient formed with increasing concentrations of NaCl. The fractions under the peak are pooled and filtered through a 0.22um filter before overnight precipitation with 8% PEG 8000. CaCl₂ is added to 25mM and the purified particles are pelleted and then resuspended in HBS#2: 150mM NaCl, 50mM Hepes pH7.4.

Briefly, 8×10^8 or 8×10^9 particles of the resulting FGF-5 virus were used to infect 293 cells, which were simultaneously treated with 3 uM etoposide to enhance viral expression levels. At 24 hours post-infection, tissue culture media and cell lysates were harvested and analysed by Western blotting. Briefly, protein samples were run on a 4-20% tris-glycine gradient gel, and transferred to nitrocellulose by standard procedures. After blocking with 5% milk in PBS, the membrane was incubated with an anti-human FGF-5 antibody (R and D systems, made in goat) at a dilution of 1:1,000 for one hour at room temperature. After the membrane was washed 3 times in PBS + 0.05% Tween-20, it was incubated with an anti-goat secondary antibody conjugated to peroxidase (1:5,000 dilution). The membrane was then washed and the FGF-5 protein detected by chemiluminescence.

Results of the Western blot are shown in Figure 4. Briefly, lane 1 represents 50 ng of the 29.5 Kd recombinant FGF-5 protein (R and D systems). Lane 2, media from cells infected with 8×10^9 viral particles and treated with etoposide, shows no FGF-5 expression. Lane 3 is an uninfected cell lysate control. Lane 4 and 5 are lysates from cells infected with 8×10^8 or 8×10^9 viral particles, respectively, and Lanes 6 and 7 are lysates from cells infected with 8×10^8 or 8×10^9 viral particles and treated with 3 uM etoposide. Lanes 4-7 all show positive FGF-5 expression. Lane 8 is a negative control of lysate from uninfected cells.

In summary, although the FGF-5 signal sequence was intact, FGF-5 protein was detected in the cell lysate only.

C. Cloning FGF-5 Lacking a Signal Sequence, into rAAV pD10-CMV.

Oncogenic activity is associated with the wild-type FGF-5 molecule (Zhan et al., 1988; Bates et al., 1991). To improve its safety, the codons for the first 21 amino acids of FGF-5's signal sequence were removed by PCR amplification of the

above pD10-CMV-FGF-5 plasmid with the following primers:
AGA/TAT/AAG/CTT/AC C/ATG/GGT/GAA/AAG/CG T/CTC/GCC/CCC/AAA (5',
5FGFMUTB; SEQ I.D. No.) and CGC/GCG/CTC/GAG/AC
C/ATG/AGG/AAT/ATT/AT C/CAA/AGC/GAA/ACT (3', 3FGF5WT; SEQ I.D. No.
5 ____). The 5' primer contains point mutations which destabilize G/C rich hairpin
structures of the FGF-5 mRNA, and should increase levels of gene expression. The
PCR product was digested with HindIII and XhoI (restriction sites introduced by the
primers), and cloned by standard methods, into the pD10 vector digested with the same
enzymes. The pD10-CMV-FGF-5 (sig-) vector is illustrated schematically in Figure 5.

10 In summary, the pD10-CMV-FGF-5 (sig-) plasmid contains the CMV
immediate/early enhancer + promoter, the CMV intron A, the FGF-5 coding region
with the modifications described in Example C above, the bovine growth hormone
polyA site, and the AAV ITR sequences. There is a 1353 bp insertion of PhiX 174
bacteriophage DNA clones into the NotI site between one ITR and the CMV immediate.
15 early enhancer + promoter region.

D. Western Analysis of 293 Cells Transfected with pD10-CMV-FGF-5 (sig-).

Expression of FGF-5 protein was demonstrated by transient transfection
of 293 cells with the plasmid pD10-CMV-FGF-5 (sig-), by standard methods. After 48
hours, tissue culture media and cell lysates were harvested. Western analysis was
20 performed with an anti-human FGF-5 antibody (R and D systems) as described above.

Results of the Western analysis are provided below in Figure 6. Briefly,
lane 1 represents 50 ng of the 29.5 Kd recombinant FGF-5 protein (R and D systems).
Lanes 2 and 3, showing FGF-5 expression, are cell lysates from 293 cells transfected
with two different clones of the pD10-CMV-FGF-5 sig- plasmid. Lane 4 is lysate from
25 cells transfected with a negative control plasmid CMV-Epo. Lanes 5, 6 and 7 represent
media from cells transfected with different clones of the pD10-CMV-FGF-5 sig-
plasmid, respectively, and the CMV-Epo plasmid. As is evident from this figure, FGF-
5 protein was detected in the cell lysate only.

E. Generation of FGF-5 (signal -) rAAV.

30 FGF-5 (sig-) rAAV virus is packaged using the triple transfection
method described in more detail above.

F. Cloning FGF-18 into the pD10-CMV rAAV Vector.

The FGF-18 coding region (see U.S. Provisional Application Serial No. 60/083,553) was cloned into the pD10-CMV vector as a PstI to EcoRV fragment, using restriction sites found in both the FGF-18 and the multiple cloning site of the pD10-CMV vector. The vector contains a 1353 bp insertion of PhiX174 bacteriophage DNA (see Example A).

A schematic illustration of pD10-CMV-FGF-18 is provided in Figure 7. Briefly, this plasmid contains the CMV immediate/early enhancer + promoter, the CMV intron A, the FGF-18 coding region, the bovine growth hormone polyA site, and the AAV ITR sequences. There is a 1353 bp insertion of PhiX 174 bacteriophage DNA cloned into the NotI site between one ITR and the CMV immediate early enhancer + promoter region.

G. Analysis of 293 Cells Transfected with pD10-CMV-FGF-18 Plasmid.

Expression of FGF-18 protein was assessed by transient transfection of 293 cells followed by Western analysis, using standard methods. Cell lysates and tissue culture media were harvested at 48 hours post transfection. An anti-peptide FGF-18 rabbit polyclonal antibody, generated against a selected polypeptide from recombinant FGF-18, was used at a dilution of 1:2,500 for one hour at room temperature. The secondary antibody, an anti-rabbit IgG conjugated to peroxidase, was used at a dilution of 1:25,000.

Results of the Western analysis are provided in Figure 8. Briefly, lanes 1-3 represent 1, 2 and 10 ul of tissue culture media from cells transfected with the pD10-CMV-FGF-18 plasmid. Lane 4 is blank. Lanes 5, 6 and 7 contain 2, 10 and 20 ul of lysate from the transfected cells. Lanes 8 and 9 are negative controls; 20 ul of tissue culture media and cell lysate, respectively, from uninfected cells. Lane 10 contains a positive control; an FGF-18-maltose binding protein fusion ((MBP); predicted size = 80 Kd, larger than the FGF-18 protein).

H. Packaging of the pD10CMV-FGF-18 plasmid into rAAV particles

FGF-18 rAAV virus was generated by the triple transfection method.

EXAMPLE 5

AAV – LACZ INJECTED RETINA

A. Subretinal injection of rAAV

Albino Sprague-Dawley rats were injected at 14 –15 days postnatal (P14- P15). Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. Subretinal injections of 2-3 μ l of AAV-CMV-Lac-Z were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The contralateral eye was either uninjected, injected subretinally with PBS, or with a control rAAV containing a reporter gene.

B. Staining Protocol

Cryosections of the retina were stained with Bluo-gal for b-galactosidase reaction product of lacZ. In all wild type rats tested (3), positive staining was visible in the interior of the whole eyecup upon gross examination (see Figure 9). 100 μ m thick agarose or 20 μ m thick cryosections of retinas indicated that most of the b-gal positive staining localized to the photoreceptors. There were a small number of LacZ positive retinal ganglion cells observed.

C. Anti-b-galactosidase immunocytochemistry

Sections from 3 wildtype and 2 transgenic rats were stained with a polyclonal antibody against b-galactosidase. These results were comparable to the bluo-gal results, primarily demonstrating photoreceptor-specific staining. Two out of five rats showed no positive staining.

D. Results

Subretinal injection of 2 ul of AAV-CMV-lacZ effectively transduced a large number of photoreceptor and retinal pigment epithelial (rpe) cells following a single intraocular inoculation of AAV-CMV-lacZ into the subretinal space (SRS) of the rat eye. The lateral extent of lacZ reporter gene expression was typically 1/3 to 1/2 of the retinal expanse following a single AAV-CMV-LacZ injection. This finding was confirmed by bluo-gal staining of the b-galactosidase reaction product of the lacZ gene as well as by immunocytochemistry using an antibody specific for b-galactosidase. The AAV-CMV-lacZ vector was effective at transducing photoreceptor and RPE cells in both the normal (wildtype) and affected, degenerating (transgenic) rat retina.

EXAMPLE 6

RETINAL TISSUE ANALYSIS OF RAAV-FGF-2 INFECTED CELLS, VS. CONTROLS

A. Subretinal injection of rAAV

Line 3 albino transgenic rats (P23H-3) on an albino Sprague-Dawley background (produced by Chrysalis DNX Transgenic Sciences, Princeton, NJ) were injected at the ages of P14 or P15. Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of 2 μ l were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The intent was to inject into the subretinal space of the posterior superior hemisphere, but we sometimes found histologically that the injection site was located just inferior to the optic nerve head. The opposite eye was either uninjected, injected subretinally with PBS, with control rAAV containing no neurotrophin or containing proteins not known to possess neurotrophic properties.

B. Histopathology Protocol / Retinal tissue analysis

The rats were euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 % glutaraldehyde). Eyes were removed and embedded in epoxy resin, and 1 μ m thick histological sections were made along the vertical meridian. Tissue sections were aligned so that the ROS and Müller cell processes crossing the inner plexiform layer were continuous throughout the plane of section to assure that the sections were not oblique, and the thickness of the ONL and lengths of RIS and ROS were measured as described (LaVail, et al) . Briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. These data were either averaged to provide a single value for the retina, or plotted as a distribution of thickness or length across the retina. We also compared the greatest 3 contiguous values for ONL thickness in each retina, to determine if any region of retina (*e.g.*, nearest the injection site) showed proportionally greater rescue; although most of these values were slightly greater than the overall mean of all 54 values, they were no different from control values than the overall mean. Thus, the overall mean was used in the data cited, since it was based on a much larger number of measurements.

C. Results

Two surgical methods of delivery of rAAV-CMV-FGF2 were completed, intravitreal and subretinal injection.

1. Intravitreal injection

5 RAAV-CMV-FGF-2 was injected into the right eye of nine transgenic S334ter rats after day P15 (the left eye was not injected). S334(4) transgenic animals were used to assess the rescue effect of rAAV-CMV- FGF-2 on degenerating photoreceptor cells when delivered by intravitreal injection. The rats were all sacrificed at age p60 and the embedded in plastic and sectioned to assess morphology and
10 therapeutic effect as assayed by the preservation of thickness of outer nuclear layer. Superior and inferior regions of eyecup are quantitated by measuring the ONL thickness using a BioQuant morphometric measuring system (BioQuant). Injected eyes were evaluated along with uninjected control eyes.

15 Control Left superior – 16.52 +/- 2.77 um
Injected Right superior – 19.71 +/- 5.27 um

Control Left inferior – 22.64 +/- 2.11 um
Injected Right inferior – 26.47 +/- 3.55 um

20

Based upon these results it was evident that there is a rescue effect of AAV-CMV-FGF-2 when delivered intraocularly into the vitreous cavity.

2. Subretinal injection of rAAV-CMV-FGF-2

Experiment A. - Location of injection – subretinal , 7 rats-both right and
25 left eyes injected, 3 rats-(left eye = uninjected). Number of rats injected – 10 rats all wild type p15 on day of injection. One rat was sacrificed every week starting at week 2. Expression of FGF-2 was assessed, as well as any signs of inflammation or neovascularization.

Experiment B. - Location of injection – subretinal, 5 rats- right eyes
30 injected w/vector left eyes injected with PBS, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 11 transgenic S334(4) rats – all were p15 on day of injection. The rats were sacrificed at age p60 and the embedded in plastic and sectioned to assess histopathology and number of surviving photoreceptor cells. .

Anatomic indication of therapeutic effect (photoreceptor rescue) was assessed histologically. Briefly, eyes injected with rAAV-CMV-FGF2 retained significantly more photoreceptors at P60, P75 and P90 than uninjected contralateral control eyes of the same animal. Retinas receiving a subretinal injection of AAV-CMV-FGF2 at P14-15 retained 71% of the normal ONL thickness, compared to about 47% in the uninjected controls (see Figures 11, 12, 13 and 14).

There was little or no rescue in PBS-injected control eyes ($p > 0.169$ in all cases). This is consistent with previous reports that needle injury to the retina in young rats (P14-P15) does not rescue photoreceptors or up-regulate bFGF mRNA expression.

10 3. Subretinal injection of rAAV-CMV-FGF-2

Two to three microliters of rAAV-CMV-FGF-2 vector was injected into the subretinal space between the photoreceptors and the adjacent retinal pigment epithelium at P14 or P15. Rats were sacrificed and eyes examined at time points between P60-P90. At these ages in uninjected control eyes of S334ter rats, the ONL thickness, which is an index of photoreceptor cell number, was reduced to about 60% of normal.

Evidence of anatomic rescue was found to be significant to the $p = .005$ confidence level in retinas transfected by rAAV-CMV-FGF-2 when compared to the control AAV vectors or sham injection of PBS by ANOVA (analysis of Variance statistical measures). JMP statistical analysis software (Copyright (c) 1999 SAS Institute Inc. Cary, North Carolina, USA).

EXAMPLE 7

ANTIBODY STAINING OF RAAV-FGF-2 INFECTED CELLS

A. Injection Protocol

25 Albino Sprague-Dawley rats were injected with rAAV-CMV-FGF-2 at the ages of P14 or P15 essentially as follows. Briefly, wild-type animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of 2-3 ul of rAAV-CMV-FGF-2 were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The contralateral eye was either uninjected, injected subretinally with PBS, wild-type rAAV, or with rAAV-CMV-lacZ.

B. Staining Protocol

Fixed eyecups were embedded in OCT and cryosectioned in 20um thick sections. Sections from 10 wt rats were stained with antibody to FGF-2. (primary- anti-FGF-2 1:500 (commercial antibody purchased from R&D systems) (secondary-anti-goat Cy3 conjugate (Sigma, St. Louis. MO)

C. Results

Immunohistochemistry was used to look for expression of FGF-2 in the eye. Two rats were examined every week starting at 3 weeks post-injection. Retinas were examined for expression of FGF-2 and also examined histopathologically for signs of inflammation or neovascularization.

Results are shown in Figure 15. Briefly, expression of FGF-2 was found in retinal photoreceptor cells as well as RPE cells at 35 days following inoculation with 2-3 ul of rAAV-CMV-FGF-2. Less significant expression was noted in retinal bipolar interneurons and retinal ganglion cells (RGCs) following injection into the subretinal space (SRS). No significant staining above background was observed in sections injected with PBS or rAAV-CMV-lacZ vectors.

EXAMPLE 8**RETINAL TISSUE ANALYSIS OF RAAV-FGF-5 AND -18 INFECTED CELLS, VS. CONTROLS****A. Subretinal injection of rAAV**

Line 4 albino transgenic rats (S334ter-4) on an albino Sprague-Dawley background (produced by Chrysalis DNX Transgenic Sciences, Princeton, NJ) were injected at age P15. Animals were anesthetized by ketamine/xylazine injection, and a local anesthetic (proparacain HCl) was applied topically to the cornea. An aperture was made through the inferior cornea of the eye with a 28 gauge needle. The subretinal injections of 2.5 µl were then made by inserting a blunt 32 gauge needle through the opening and delivering the rAAV suspension into the subretinal space in the posterior retina. The opposite eye was either uninjected, injected subretinally with PBS, with control rAAV containing no neurotrophin or containing proteins not known to possess neurotrophic properties.

B. Histopathology Protocol / Retinal tissue analysis

The rats were euthanized by overdose of carbon dioxide inhalation and immediately perfused intracardially with a mixture of mixed aldehydes (2% formaldehyde and 2.5 % glutaraldehyde). Eyes were removed and embedded in epoxy

resin, and 1 μ m thick histological sections were made along the vertical meridian. Tissue sections were aligned so that the ROS and Müller cell processes crossing the inner plexiform layer were continuous throughout the plane of section to assure that the sections were not oblique, and the thickness of the ONL was measured as described (LaVail, et al 19XX). Briefly, 54 measurements of each layer or structure were made at set points around the entire retinal section. The 27 measurements from the inferior region and the superior region of the retina were averaged separately to give two values for each eye. This separation was made because the retina degenerates at different rates in these two regions of the S334ter-4 animal model.

10 C. Results

Sub-retinal injections of both rAAV-CMV-FGF-5 and rAAV-CMV-FGF-18 were performed.

1. Sub-retinal injection of rAAV-CMV-FGF-5

Experiment. - Location of injection – subretinal, 3 rats- right eyes injected w/vector left eyes injected with PBS, 8 rats- right eyes injected w/vector left eyes injected with rAAV-CMV-LacZ, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 15 transgenic S334ter-4 rats – all were p15 on day of injection. The rats were sacrificed at age p60. The retinas were embedded in plastic and sectioned to assess histopathology and number of surviving photoreceptor cells.

Anatomic indication of therapeutic effect (photoreceptor rescue) was assessed histologically. The injection of rAAV-CMV-FGF-5 resulted in significant rescue of photoreceptors, compared to PBS injected, rAAV-CMV-LacZ injected, and uninjected eyes (see Figure 33). The rescue was significant to the $p=.05$ confidence level for all three comparisons, by ANOVA (analysis of Variance statistical measures). JMP statistical analysis software (Copyright (c) 1999 SAS Institute Inc. Cary, North Carolina, USA).

2. Sub-retinal injection of rAAV-CMV-FGF-18

Experiment. - Location of injection – subretinal, 3 rats- right eyes injected w/vector left eyes injected with PBS, 3 rats- right eyes injected w/vector left eyes injected with rAAV-CMV-LacZ, 4 rats- right eyes injected w/vector (left eye = uninjected). Number of rats injected – 10 transgenic S334ter-4 rats – all were p15 on

day of injection. The rats were sacrificed at p60, and the retinas embedded in plastic and sectioned.

Eyes injected with rAAV-CMV-FGF-18 retained significantly more photoreceptors at P60 than PBS injected, rAAV-CMV-LacZ injected, or uninjected control eyes. Each comparison, by ANOVA, was statistically significant to the $p=0.05$ confidence level.

EXAMPLE 9

IN VIVO DELIVERY TO RETINAL GANGLION CELLS (RGCs)

A. Intra-vitreous injection of AAV vectors

All surgical procedures were performed in female adult Sprague-Dawley rats (180-200 g; Charles River Breeders) under general anesthesia (7% chloral hydrate; 0.42 mg per g of body weight, i.p.) in accordance with the Use of Animals in Neuroscience Research and McGill University Animal Care Committee guidelines for the use of experimental animals.

Briefly, rAAV-CMV-lacZ (5 μ l; see above) was injected into the vitreous chamber in the superior (dorsal) hemisphere of the retina using a posterior approach as described (Di Polo, PNAS, 1998). Control eyes were injected with equal volumes of Hepes-buffered saline (HBS, virus vector).

B. Identification of RPCs

For visualization of RGCs, neurons were retrogradely labeled with the fluorescent tracer Fluorogold (Fluorochrome, Englewood, CO) at 2% in 0.9% NaCl containing 10% dimethyl sulfoxide by application of the tracer to both superior colliculi 7 days prior to analyses as described (Vidal-Sanz *et al.*, 1988). Anesthetized rats were then perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer (PB, pH 7.4) and the eyes were immediately enucleated. The anterior part of the eye and the lens were removed and the remaining eye cup was immersed in the same fixative for 2 hr at 4°C. Eye cups were cryoprotected in graded sucrose solutions (10-30% in PB) for several hours at 4°C, embedded in O.C.T. compound (Tissue-Tek, Miles Laboratories, Elkhart, IN) and frozen in a 2-methylbutane/liquid nitrogen bath. Retinal radial cryosections (12-15 μ m), obtained along the vertical meridian of the eye, were collected onto gelatin-coated slides and processed for immunocytochemistry. Alternatively, entire eyes were rinsed three times (15 min each) in PBS at room temperature with gentle shaking, to whole-mount histochemical staining as described below.

C. Histochemical Analysis

Expression of the bacterial LacZ gene in whole retinas was detected by standard histochemical staining reactions using halogenated indoyl- β -D-galactoside (Bluogal; GIBCO BRL). Following removal of the anterior eye structures and lens, eye cups were incubated overnight in a staining solution containing 5mM K-ferricyanide, 5 mM K-ferrocyanide, 2 mM MgCl₂, and 0.5 mg/ml Bluogal at 37°C. Retinas were then dissected, fixed for an additional 30 min and flat-mounted vitreal side up on glass slides.

For visualization of the AAV-mediated lacZ gene product in retinal radial sections, cryosections were incubated in 10% normal goat serum (NGS) in 0.2% Triton X-100 (Sigma, St. Louis, MO) in phosphate buffer saline (PBS) for 30 min at room temperature to block non-specific binding. Two primary antibodies raised against the lacZ gene product were used with similar results. A polyclonal anti-beta-gal antibody (diluted 1:1000; 5 prime→3 prime, Inc., Boulder, CO) and a monoclonal anti-LacZ antibody (diluted 1:500; Promega, Madison, WI). Primary antibodies were added in 2% NGS in 0.2% Triton X-100 and incubated overnight at 4°C. Sections were subsequently processed with anti-rabbit Cy3-conjugated IgG (diluted 1:500, Jackson Immunoresearch, West Grove, PA) or anti-mouse Cy3-conjugated IgG (diluted 1:500, Jackson Immunoresearch) and mounted. Control sections were treated in the same way but with omission of the primary antibody. Sections were visualized by fluorescent microscopy (Polyvar, Reichert-Jung).

Expression of the heparan sulfate proteoglycan receptor in the retina was examined using a monoclonal anti-heparan sulfate antibody (HepSS-1, diluted 1:1,000, Seikagaku Corporation, Tokyo, Japan). Following overnight incubation at 4°C, sections were processed with biotinylated anti-mouse Fab fragment (Jackson Immunoresearch), avidin-biotin-peroxidase reagent (ABC Elite Vector Labs, Burlingame, CA), followed by reaction in a solution containing 0.05% diaminobenzidine tetrahydrochloride (DAB) and 0.06% hydrogen peroxide in PB (pH 7.4) for 5 min. For analysis of co-localization of heparan sulfate in Fluorogold-labeled neurons, sections were processed with Cy3-coupled anti-mouse IgG (Jackson Immunoresearch) after incubation in primary antibody. In all cases, the primary antibody was omitted in control sections. Sections were mounted and visualized by light or fluorescent microscopy.

Quantification of AAV-transduced cells in the ganglion cell layer of retinal flat-mounts was performed in two ways: i) by counting the entire number of Bluogal positive cells in each of the retinal quadrants (superior, inferior, temporal and nasal); and ii) by counting the number of cells in three standard areas (at 1, 2 and 3 mm

from the optic disc) of each quadrant as previously described (Villegas-Perez *et al.*, 1993).

For quantification of Fluorogold, Blue-gal or HepSS-1 positive cells in retinal radial sections, the entire number of labeled cells per section was counted under fluorescent microscopy. Four to five serial sections per eye were routinely counted and a mean value per animal was obtained, followed by the calculation of a mean value for the entire experimental group which consisted of 4-5 rats. Results were analyzed using the Sigmastat program (Jandel, San Rafael Madera, CA) by a student's *t* test (paired groups).

10 D. Results

Analysis of retinas from eyes that received a single intravitreal injection of rAAV-CMV-lacZ demonstrated a large number of LacZ-positive cells throughout the entire GCL as assessed by histochemical LacZ staining of both flat-mounts (Figure 16A) and radial sections (Figure 16B). In many cases, RGCs transduced by AAV could be unequivocally identified because the LacZ reaction product filled their axons that converged at the level of the optic nerve head. In addition, LacZ-positive photoreceptor nuclei were observed but were always restricted to the vicinity of the injection site (not shown). No staining was observed in control eyes injected with virus vector. No signs of cytotoxic damage or cellular immune reaction to the viral vector were observed in any of the retinas examined.

Quantification of LacZ-positive cells in the GCL of retinal flat-mounts demonstrated a 2.8-fold increase between 2 and 4 weeks after intravitreal injection of the rAAV-CMV-lacZ vector (Figure 17). For example, we found $27,569 \pm 7,646$ cells/retina (mean \pm S.D.; $n=3$) and $79,043 \pm 10,321$ cells/retina ($n=4$) expressing the LacZ gene product at 2 and 4 weeks after intraocular administration of the vector, respectively. A comparable number of cells expressing the AAV-mediated transgene at 4 weeks was observed at 8 weeks ($70,221 \pm 12,500$; $n=3$) following rAAV-CMV-lacZ injection. Although the majority of LacZ-positive cells were observed in the superior hemisphere at 2 weeks after virus administration, there was robust transgene expression throughout the entire retina by 4 and 8 weeks as assessed by quantification of Lac-Z positive cell densities in all retinal quadrants at these time points (Figure 17).

To identify the cellular localization of the AAV-mediated LacZ gene product, we combined immunocytochemical staining of LacZ with retrograde tracing of RGC bodies using Fluorogold backlabeling from the superior colliculi. Double-labeling experiments indicated that the majority of cells in the GCL expressing the LacZ gene

product were also Fluorogold-positive (Figure 18). Analysis of the number of Fluorogold-labeled cells in the GCL expressing the LacZ gene product indicated that 300 ± 29 (mean \pm S.D.; $n=4$) expressed both markers out of 330 ± 32 Fluorogold-labeled cells (the average RGC population per retinal radial section). This indicates that ~92% of RGCs, identified by the Fluorogold label, also expressed the AAV-mediated LacZ gene product (Figure 19). In all retinas examined, we routinely observed a number of Lac-Z positive cells that were not labeled with Fluorogold (Figures 18 and 19). Thus, it is possible that these cells are displaced amacrine cells or RGCs that failed to incorporate the retrograde tracer. Together, these results indicate that RGCs are preferentially transduced by recombinant AAV following intravitreal injection of this viral vector.

To investigate the molecular mechanisms underlying preferential transduction of RGCs by AAV, we first examined the expression of the heparan sulfate proteoglycan, which mediates both AAV attachment and infection of target cells (Summerford *et al.*, 1998), in the adult retina. Immunostaining of retinal radial sections with a specific antibody against heparan sulfate (HepSS-1) demonstrated robust staining in the GCL (Figure 20). Positive immunolabeling was clearly visualized in both neuronal somata and axonal bundles in the fiber layer. More diffuse and sparse staining was observed in some photoreceptor nuclei and cells in the inner nuclear layer. No staining was observed in control retinal sections in which the primary antibody was omitted (not shown).

To determine the cell type within the GCL that express the heparan sulfate proteoglycan receptor, we performed a double-labeling study in which RGCs were first retrogradely labeled from the superior colliculi followed by immunostaining of retinal sections with HepSS-1. Our analysis showed that 299 ± 23 (mean \pm S.D.; $n=4$) cells in the GCL expressed both Fluorogold and HepSS-1 markers out of 315 ± 34 Fluorogold-labeled cells which represent the average RGC population visualized per retinal radial section. The large population of RGCs (~95%) expressing heparan sulfate proteoglycan receptor correlated well with the number of RGCs expressing the AAV-mediated transgene product (~92%). Together, these data suggest that preferential transduction of adult RGCs by recombinant AAV is mediated by the heparan sulfate proteoglycan receptor expressed by these neurons.

EXAMPLE 10

CONSTRUCTION OF A RAAV VECTOR EXPRESSING
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) 165

5 The human VEGF-165 cDNA was cloned from the PCR-Blunt II Topo Vector (Invitrogen) into the pD10-CMV rAAV vector as an EcoR1 fragment (pD10-VEGFuc). The pD10-VEGFuc vector is illustrated schematically in Figure 21, and its nucleotide sequence is shown in Figure 22. The VEGFuc rAAV virus was packaged using the triple transfection method and purified by column chromatography.

10 Briefly, a cell pellet is resuspended in TNM buffer: 20mM Tris pH 8.0, 150mM NaCl, 2mM MgCl₂. Deoxycholic Acid is added to 0.5% to lyse the cells. 50u/ml Benzonase is added and the lysed cells are incubated at 37 degrees to digest any nucleic acids. The cell debris is pelleted and the supernatant is filtered through a 0.45um filter and then a 0.22um filter. The virus is then loaded onto a 1.5ml Heparin
15 sulfate column using the Biocad. The column is then washed with 20mM Tris pH 8.0, 100mM NaCl. The rAAV particles are eluted with a gradient formed with increasing concentrations of NaCl. The fractions under the peak are pooled and filtered through a 0.22um filter before overnight precipitation with 8% PEG 8000. CaCl₂ is added to 25mM and the purified particles are pelleted and then resuspended in HBS#2: 150mM
20 NaCl, 50mM Hepes pH7.4.

EXAMPLE 11

INFECTION OF 293 CELLS WITH D10-VEGF RAAV RESULTS IN
VEGF PROTEIN EXPRESSION

25 The functionality of the viral particles was assessed by infection of 293 cells with 3 different viral multiplicities of infection (MOIs); 1 x 10e7, 1 x 10e8 and 1 x 10e9 viral particles per 4 x 10e5 293 cells, in the presence of 1.5 uM etoposide. At 48 hours post infection, tissue culture media (supers) and cell lysates were harvested. VEGF protein levels were determined using a Quantikine human VEGF sandwich ELISA kit
30 (R and D Systems, see Figure 23). VEGF protein concentrations are given in pg/ml. The two highest MOIs gave values significantly above that of the cells infected with a negative control virus. The levels of secreted VEGF were approximately 4-7 fold higher than those of the lysates.

EXAMPLE 12

INFECTION OF RETINAL PIGMENT EPITHELIAL (RPE) CELLS WITH D10-VEGF RAAV
RESULTS IN VEGF PROTEIN SECRETION

5 VEGF expression levels in a monolayer of cultured primary (or very early passage) human fetal RPE cells infected with D10-VEGF 165 rAAV were clearly elevated relative to endogenous levels. Cells were infected with a range of rAAV particles from 0 to 1×10^5 per cell. VEGF expression was dose dependent, increased over time, and secretion appeared to be somewhat higher from the apical surface. In a
10 representative experiment, RPE cells infected with 1×10^5 viral particles secreted $> 100 \text{ ng}/1 \times 10^6$ cells from the apical surface and $50 \text{ ng}/1 \times 10^6$ cells from the basal surface at 8 days post infection. The polarity of VEGF secretion from human fetal RPE cells infected with 3 different MOIs is shown in Figure 24.

EXAMPLE 13

15 INFECTION OF RETINAL PIGMENT EPITHELIAL (RPE) CELLS WITH VEGF RAV RESULTS
IN VEGF PROTEIN SECRETION AND DECREASED MEMBRANE CONDUCTANCE

Infection of cultured human fetal RPE cells with recombinant VEGF adenovirus (AV) results in secretion of very high levels of VEGF from both the apical
20 and basal surfaces of the RPE. MOI's of 0 to 1,000 or 0 to 10,000 particles per cell were used in two separate experiments. In both cases, expression levels increased over time, peaking at approximately $100\text{--}200 \text{ ug}/1 \times 10^6$ cells at the highest MOI's (see Figure 25). In addition, the total transepithelial membrane resistance of the RPE monolayer decreased significantly at all MOIs, and by approximately 4-5 fold at the
25 highest MOIs (see Figure 26).

EXAMPLE 14

CONSTRUCTION OF A RAAV VECTOR EXPRESSING SOLUBLE FLT-1 (SFLT-1) RECEPTOR

The sFlt-1 cDNA was cloned from the Blunt II Topo Vector (Invitrogen)
30 into the pD10-CMV rAAV vector as an EcoRI fragment (pD10-sFlt-1). The pD10-sFlt-1 vector is illustrated schematically in Figure 27, and its nucleotide sequence is shown in Figure 28. The human sFlt-1 rAAV virus was packaged using the triple transfection technique and purified by column chromatography.

EXAMPLE 15

IN VITRO ASSAY FOR ANTI-ANGIOGENIC ACTIVITY

This example describes the HUVEC (human umbilical vein endothelial cell) proliferation assay, which can be utilized to determine the anti-angiogenic activity of a molecule (see generally, Gerritsen *et al*, 1999. JBC 274:9116-9121). Briefly, HUVEC cells are seeded on collagen-coated 96-well plates at 6,000 cells/cm² in Clonetics EGM media. EGM media contains endothelial cell growth supplements, 10% fetal bovine serum, 2mM L-glutamine, and antibiotics. Cells are allowed to attach for 4 hours. Medium is then replaced with 40 ng/ml bFGF, 40 ng/ml VEGF, and 80 nM PMA in 1X basal medium consisting of M199 supplemented with 1% fetal bovine serum, 1X ITS, 2 mM L-glutamine, 50 ug/ml of ascorbic acid, 26.5 mM NaHCO₃, and appropriate concentration of antibiotics. Cells are cultured in the above medium in the presence of the sample supernatant or vector for 4 hours. The sample supernatant would come from 293 cells transfected with the appropriate plasmid construct expressing the molecule we are testing for anti-angiogenic activity. Finally, 5 uL (100uM) of 5-bromo-2'-deoxyuridine (BrdU) is added in a final volume of 100 uL/well, and cells were incubated for another 20 hours. BrdU incorporation was evaluated by an enzyme-linked immunosorbent assay kit from Boehringer Mannheim.

20

From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

CLAIMS

We claim:

1. A method of treating or preventing diseases of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of a neurotrophic factor, such that said disease of the eye is treated or prevented.
2. The method according to claim 1 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.
3. The method according to claim 1 wherein said neurotrophic factor is a FGF.
4. The method according to claim 3 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.
5. The method according to claim 1 wherein said disease of the eye is macular degeneration.
6. The method according to claim 1 wherein said disease of the eye is diabetic retinopathy.
7. The method according to claim 1 wherein said disease of the eye is an inherited retinal degeneration.
8. The method according to claim 7 wherein said inherited retinal degeneration is retinitis pigmentosa.
9. The method according to claim 1 wherein said disease of the eye is glaucoma.
10. The method according to claim 1 wherein said disease of the eye is a surgery-induced retinopathy.

11. The method according to claim 1 wherein said disease of the eye is retinal detachment.
12. The method according to claim 1 wherein said disease of the eye is a photic retinopathy.
13. The method according to claim 1 wherein said disease of the eye is a toxic retinopathy.
14. The method according to claim 1 wherein said disease of the eye is a trauma-induced retinopathy.
15. The method according to claim 1 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
16. The method according to claim 1 wherein said gene delivery vector is a recombinant adeno-associated viral vector.
17. A method of inhibiting neovascular disease of the eye, comprising, administering intraocularly a gene delivery vector which directs the expression of an anti-angiogenic factor, such that said neovascular disease of the eye is inhibited.
18. The method according to claim 17 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, and soluble Tie-2 receptor.
19. The method according to claim 17 wherein said neovascular disease of the eye is diabetic retinopathy, wet ARMD, and retinopathy of prematurity.
20. The method according to claim 17 wherein said gene delivery vector is a retrovirus selected from the group consisting of HIV and FIV.
21. The method according to claim 17 wherein said gene delivery vector is a recombinant adeno-associated viral vector.

22. A gene delivery vector which directs the expression of a neurotrophic factor, or an anti-angiogenic factor.

23. The gene delivery vector according to claim 22 wherein said neurotrophic factor is NGF, BDNF, CNTF, NT-3, or, NT-4.

24. The gene delivery vector according to claim 22 wherein said neurotrophic factor is a FGF.

25. The gene delivery vector according to claim 22 wherein said FGF is FGF-2, FGF-5, FGF-18, FGF-20, or, FGF-21.

26. The gene delivery vector according to claim 22 wherein said anti-angiogenic factor is soluble Flt-1, PEDF, and soluble Tie-2 receptor.

27. The gene delivery vector according to claim 22 wherein said vector is generated from a retrovirus.

28. The gene delivery vector according to claim 27 wherein said retrovirus is HIV or FIV.

29. The gene delivery vector according to claim 22 wherein said vector is generated from a recombinant adeno-associated virus.

1/36




Fig. 1

SUBSTITUTE SHEET (RULE 26)

2/36

ACCATGTAGCGGCCCTGCGCGCTCGCTCGCTCACTGAGGCGGCCGCGGCAAGCCGGGCGTCGGGCGACCTTTGGT
CGCCCGGCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGCCAACTCCATCACTAGGGGTTCTTGTTAGTTAAT
GATTAACCCGCGCATGCTACTTATCTACGTAGCCATGCTCTAGGGAATTGGCCGCGGAATTCGACTCTAGGCCATTG
CATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGACATTGATT
ATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAAC
TTACGGTAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCAT
GTAACGCCAATAGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCA
AGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCTGGCATTATGCCAGTACA
TGACCTTACGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTGG
CAGTACACCAATGGGCGTGGATAGCGGTTTGACTCAGGGGATTTCCAAGTCTCCACCCATTGACGTCAATGGGAG
TTTGTGTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCGTTGACGCAAATGGGCGTA
GGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAGATCGCTGGAGACGCCATCCACGC
TGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGCAATTGGAACGCGGATTCC
CCGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGT
TTTTGGCTTGGGGCTATACACCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTAT
TGACCATTATTGACCCTCCCTATTGGTGACGATACTTCCATTACTAATCCATAACATGGCTCTTTGCCACAAC
ATCTCTATTGGCTATATGCCAATACTCTGTCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGGGTCCA
TTTATTATTACAAATTCACATATAACAACGCGTCCCGGTGCCCGCAGTTTTTATTAAACATAGCGTGGGATC
TCCGACATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTC
CCATCCGTCCAGCGGCTCATGGTCTCGGCAGCTCCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCACA
TGCCACCACCACAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGATTGGGCT
CGCACCTGGACGAGATGGAAGACTTAAGGCAGCGGCAGAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAA
GAGTCAGAGGTAACCTCCGTGCGGTGCTGTTAACGGTGGAGGCGAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGC
GCGCGCCACCAGACATAATAGCTGACAGACTAACAGACTGTTCCTTTCCATGGGTCTTTTCTGCAGTCACCGTCTGC
GACCTAAGAAATCAGGCCTAAGCTTCTTAGGTATCGATCTCGAGCAAGTCTAGAGGGAGACCACAACGGTTTCCCTC
TAGCGGATCAATTCGCCCCCCCCCTAACGTTACTGGCCGAAGCCGCTTGAATAAGGCCGGTGTGCGTTTGTCT
ATATGTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAACCTGGCCCTGTCTTCTTGACGAGC
ATTCTAGGGGTCTTTCCCTCTCGCCAAAGGAATGCAAGGTCTGTTGAATGTCTGAAGGAAGCAGTTCCTCTGGA
AGCTTCTTGAAGACAAACAAGCTCTGTAGCGACCTTTGACGAGCGGAACCCCCACCTGGCGACAGGTGCCTCT
GCGGCCAAAAGCCAGTGTATAAGATACCTGCAAAGGCGGCACAACCCAGTGCCACGTTGTGAGTTGGATAGTT
GTGGAAGAGTCAAATGGCTCTCCTCAAGCGTATTCAACAAGGGGTGAAGGATGCCCAGAAGGTACCCATTGTAT
GGGATCTGATCTGGGGCTCGGTGCACATGCTTTACATGTGTTTAGTCGAGGTTAAAAAACGTCTAGGCCCCCGA
ACCACGGGGACGTGGTTTTCTTTGAAAAACAGATAATACCATGGCCGCGGGAGCATCACCACGCTGCCAGCCCT
GCCGGAGGACGGCGGACGGCGCTTTCCCGCGGGCCACTTCAAGGACCCCAAGCGGCTGACTGCAAGAACGGGG
GCTTCTTCTGCGCATCCACCCGACGGCGAGTGGACGGGTCCGCGAGAAGAGCGACCCACACATCAAATACAA
CTTCAAGCAGAAGAGAGAGGGGTGTGTCTATCAAAGGAGTGTGTGCAAACGTTACCTTGCTATGAAAGAAGATGG
AAGATTACTAGCTCTAAATGTGTTACAGACGAGTGTCTTTTGAACGATTGGAGTCTAATAACTACAATACTT
ACCGGTCAAGGAAATACACGAGTTGGTATGTGGCACTGAAACGAACGGGCAGTATAAACTTGGATCCAAAACAGGA
CCTGGGCAGAAAGCTATACTTTTCTTCAATGTCTGCTAAGAGCTGATCTTAATGGCAGCATCTGATCTCATTTTA
CATGAAGCTGGTGGCATCCCTGTGACCCCTCCCAAGTGCCTCTCTGGCCCTGGAAGTTGCCACTCCAGTGCCACC
AGCCTTGCTCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCTTCTATAATATTATGGGGTGGAGGG
GGTGGTATGGAGCAAGGGCAAGTTGGGAAGACAACCTGTAGGGCTGGGGGTCTATTGGGAACCAAGCTGGAGTG
CAGTGGCACAATCTGGCTCACTGCAATCTCGGCTCTGGGTCAAGCGATTCTCTGCCTCAGCCTCCCGAGTTG

Fig. 2A

SUBSTITUTE SHEET (RULE 26)

3/36

TTGGGATTCCAGGCATGCATGACCAGGCTCAGCTAATTTTTGTTTTTTGGTAGAGACGGGGTTTACCATATTGSC
CAGGCTGGTCTCCAACCTCCTAATCTCAGGTGATCTACCCACCTTGGCCTCCCAAATTGCTGGGATTACAGGCGTGAA
CCACTGCTCCCTTCCCTGTCTCTGATTTTAAAAAATACTATACCAGCAGGAGGACGTCCAGACACAGCATAGGCTA
CCTGGCCATGCCCAACCGGTGGGACATTTGAGTTGCTTGGTGGCACTGTCTCTCATGCGTTGGGTCCACTCAGTA
GATGCCCTGTTGAATTATCGGATCCACTACGCGTTAGAGCTCGCTGATCAGCCTCGACTGTGCTTCTAGTTGCCAGC
CATCTGTTGTTTGGCCCTCCCGGTGCCTTCTTGACCTGGAAGGTGCCACTCCCACTGTCTTCTCTAATAAAAT
GAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCTATTCTTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGA
GGATTGGGAAGACAATAGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGATCATCCAGCCA
ATTCCCTAGAGCATGGCTACGTAGATAAGTAGCATGGCGGTTAATCATTAACTACAAGGAACCCCTAGTGATGGAG
TTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGCGACCAAAGGTGCGCCGACGCCGGGCTTTGC
CCGGGCGGCCCTCAGTGAGCGAGCGAGCGCGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGA
TCATCCAGCCGGCGTCCCGGAAACGATTCCGAAGCCCAACCTTTCATAGAAGGCGCGGTGGAATCGAAATCTCGT
GATGGCAGGTGGGGCTCGCTTGGTCGGTCATTTGCAACCCAGAGTCCCGCTCAGAAGAACTCGTCAAGAAGGCGA
TAGAAGGCGATGCGCTGCGAATCGGGAGCGCGATACCGTAAAGCACGAGGAAGCGGTACGCCATTGCGCGCAAG
CTCTTCAGCAATATCAGGGTAGCCAACGCTATGTCTGATAGCGGTCCGCCACACCCAGCCGGCCACAGTCGATGA
ATCCAGAAAAGCGGCCATTTCCACCATGATATTGCGCAAGCAGGCATCGCCATGGGTACGACGAGATCTCGCGG
TCGGGCATGCGCGCTTTGCGCTGGCGAACAGTTGCGCTGGCGGAGCCCTGATGCTCTTCTGTCAGATCATCTG
ATCGACAAGACCGGCTTCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCTGCTTGGTGGTGAATGGGCAGGTAG
CCGGATCAAGCGTATGCAGCGCGCATTGCATCAGCCATGATGGATACTTCTCGGCAGGAGCAAGGTGAGATGAC
AGGAGATCTGCCCCGGCACTTCCGCCAATAGCAGCCAGTCCCTTCCCGCTTCACTGACAACGTGAGCACAGCTGC
GCAAGGAACGCCCGTCTGCGCCAGCCACGATAGCCCGCTGCTCTGCTCGAGTTCATTAGGGCACCGGACAGGT
CGGTCTTGACAAAAAGAACCGGGCGCCCTGCGCTGACAGCCGGAACACGGCGGCATCAGAGCAGCCGATTGTCTGT
TGTGCCAGTCATAGCCGAATAGCTCTCCACCAAGCGGCGGAGAACCTGCGTGCAATCCATCTTGTTCATCAT
GCGAAACGATCCTCATCTGTCTCTTGATCAGATCTTGATCCCTGCGCCATCAGATCCTTGGCGGCAAGAAAGCCA
TCCAGTTTACTTTGCGAGGGTTCCTCAACCTTACCAGAGGGCGCCCGAGTGGCAATCCGGTTCGCTTGCTGTCCAT
AAAACCGCCAGTCTAGCTATCGCCATGTAAGCCCACTGCAAGCTACCTGCTTTCTCTTTGCGCTTGCCTTTCCCT
TGTCAGATAGCCAGTAGCTGACATTCATCCGGGTGACGACCGTTTCTGCGGACTGGCTTTCTACGTGTTCCGCT
TCTTTAGCAGCCCTTGCGCCCTGAGTGCTTGGCGAGCGTGAAGCTGTCAATTCGCGTTAAATTTTGTAAATC
AGCTCATTTTTTAACCAATAGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAAATAGCCCGAGATAGGGTTGAG
TGTTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATC
AGGGCGATGGCGGATCAGCTTATGCGGTGTAAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGGCGCTC
TTCCGCTTCTCTGCTCACTGACTCGCTGCGCTCGTTCGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGG
TAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC
CGTAAAAAGGCCGCTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCTGACGAGCATCACAAAAATCGACGCTCAAG
TCAGAGGTGGCGAAACCCGACAGGACTATAAGATACCAGGCGTTTCCCTTGGAAAGCTCCCTCGTGCGCTCTCTG
TTCCGACCTGCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCCGGAAGCGTGGCGCTTTCTCATAGCTCACGC
TGTAAGTATCTCAGTTCGGTGTAGGTGTTGCTCCAGCTGGGCTGTGTGCACGAACCCCCGTTACGCCGACCG
CTGCGCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG
GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCTAACTACGGCTACACT
AGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAGAGTGGTAGCTCTTGATCCGG
CAAAACAAACCCGCTGGTAGCGGGGTTTTTGTGTTGCAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCAAGA
AGATCCTTTGATCTTTCTTACTGAACGGTGATCCCCACCGGAATT

Fig. 2B

SUBSTITUTE SHEET (RULE 26)





Fig. 3

SUBSTITUTE SHEET (RULE 26)

5/36

*Fig. 4*

SUBSTITUTE SHEET (RULE 26)

6/36




Fig. 5

SUBSTITUTE SHEET (RULE 26)

7/36




Fig. 6

SUBSTITUTE SHEET (RULE 26)

8/36





Fig. 7

SUBSTITUTE SHEET (RULE 26)

9/36

1 2 3 4 5 6 7 8 9 10



SUBSTITUTE SHEET (RULE 26)

10/36




Fig. 9

SUBSTITUTE SHEET (RULE 26)

11/36




Fig. 10

SUBSTITUTE SHEET (RULE 26)

12/36




Fig. 11

SUBSTITUTE SHEET (RULE 26)

13/36




Fig. 12

SUBSTITUTE SHEET (RULE 26)

14/36




Fig. 13

SUBSTITUTE SHEET (RULE 26)




Fig. 14

16/36




Fig. 15

SUBSTITUTE SHEET (RULE 26)

17/36

AAV-LacZ Transduction of Retinal Ganglia





Fig. 16

SUBSTITUTE SHEET (RULE 26)

18/36

Time Course of AAV-Medicated Transgene
Expression in the Ganglion Cell layer



Time after intraocular injection of AAV

Fig. 17

SUBSTITUTE SHEET (RULE 26)

19/36

Localization of AAV-Medicated LacZ Gene Product in Retrograde Labeled RCG




Fig. 18

Quantification of Flourogold and LacZ Positive Cells in the Ganglion Cell Layer Following Intravitreal Injection of rAAV-LacZ




Fig. 19

21/36

Localization of Heparin sulfate Proteoglycan, the Cellular Receptor for AAV, in the Adult Rat Retina




Fig. 20

SUBSTITUTE SHEET (RULE 26)

22/36




Fig. 21


SUBSTITUTE SHEET (RULE 26)

AAACCTTGGCGCCGCGGAATTCGACTCTAGGCCATTGCATACGTTGTATCTATATCATAAATGTACATTTATATTGGCTCATGTCCAAATATGACCGCCA
TGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAA
TGGCCCGCCTGGCTGACCGCCCAACGACCCCCGCCCATTTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGACGTCAAT
GGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCCC
TGGCATTATGCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTA
CACC AATGGGCGTGGATAGCGGTTTGA CTACGGGGATTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGT TTTGGCACCAAATCAACGGGACT
TTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGTCAG
ATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGCGGCCGGGAACGGTGATTGGAACGGCGATTCC
CGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTTGGCTTGGGGCCTATACACC
CGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTGACCATTATTGACCACTCCCCATTGGTGACGATACTTTCCATTACT
AATCCATAACATGGCTCTTTGCCACAACATATCTCTATTGGCTATATGCCAATACTCTGTCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGGG
GTCCATTATTATTTACAAATTCACATATACAACAACGCCGTCCTCCCGTGCCCGCAGTTTTTATTAACATAGCGTGGGATCTCCGACATCTCGGGTACGT
GTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATCCGTCAGCGGCTCATGGTCGCTCGGCAGCTCCTTGCTC
CTAACAGTGGAGGCCAGACTTAGGCACAGCACAATGCCACCACCACAGTGTGCCGCACAAGGCCGTGGCGGTAGGGTATGTGTCTGAAAATGAGCTCGG
AGATTGGGCTCGCACCTGGACGCAGATGGAAGACTTAAGGCAGCGGCAGAGAAGATGCAGGCAGCTGAGTTGTTGTATTCTGATAAGAGTCAGAGGTAAC
TCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGGCCACCAGACATAATAGCTGACAGACTAACAGAC
TGTTCTTTCCATGGGTCTTTCTGCACTCACCGTCGTGCACTAAGAATTGCCCTTCGAAACCATGAAC TTTCTGCTGTCTTGGGTGCATTGGAGCCTT
GCCTTGCTGCTCTACCTCCACCATGCCAAGTGGTCCCAGGCTGCACCATGGCAGAGGAGGAGGGCAGAAATCATCACGAAGTGGTGAAGTTTATGGATGT
CTATCAGCGCAGCTACTGCCATCCAATCGAGACCTGGTGGACATCTTCCAGGAGTACCCTGATGAGATCGAGTACATCTTCAAGCCATCCTGTGTGCCCC
TGATGCGATGCGGGGGCTGTGCAATGACGAGGGCTGGAGTGTGTGCCACTGAGGAGTCCAACATCACCATGCAGATTATGCGGATCAAACCTCACCAA
GGCCAGCACATAGGAGAGATGAGCTTCTACAGCACAACAAATGTGAATGCAGACCAAAGAAAGATAGAGCAAGACAAGAAAATCCCTGTGGGCTTGCTC
AGAGCGGAGAAAGCATTTGTTGTACAAGATCCGCAGACGTGTAATGTTCTTGCAAAAACACAGACTCGCGTTGCAAGGCGAGGCAGCTTGA GTTAAACG
AACGTACTTGAGATGTGACAAGCCGAGGCGGTGAGCCGGGCAGGAGGAAGGAGCCTCCCTCAGGGTTTCGGGAACCAGATCTCTCACCAGGAAGACTGA
TACAGAAAGGGCGAATTACGGCCTAAGCTTCTAGGTATCGATCTCGAGCAAGTCTAGAAAGCCATGGATATCGGATCCACTACCGGTAGAGCTCGCTGA
TCAGCCTCGACTGTGCTTCTAGTTGCCAGCCATCTGTTGTTTGCCCTCCCCCGTGCTTCTTGACCTGGAAGGTGCCACTCCCACGTCTCTTCTTA
ATAAAATGAGGAAATTCATCGCATTGTCTGAGTAGGTGTATTCTATTCTGGGGGTGGGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATA
GCAGGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCCGCGCTGGAGGATCATCCAGCTAGCAAGTCCCATCAGTGATGGAGTTGGCCACTCCCTCTCTGC
GCGCTCGCTCGCTCACTGAGGCGGGGCGACCAAAGTCCGCCGACGCCCCGGCTTTGCCGGGCGGCCTCAGTGAGCGAGCGAGCGGCCAGCGATTCTCT
TGTTTGCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGCTACCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGA
ATATCATATTGATGGTGATTTGACTGTCTCCGGCTTTCTCACCCTGTTGAATCTTTACCTACACATTACTCAGGCAATTGCATTTAAATATATAGGGTT
CTAAAAATTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAAGTATTACAGGGTCATAATGTTTTTGGTACAACCGATTTAGCTTTATGCTCTGAG
GCTTTATTGCTTAATTTTGCTAATCTTTGCCCTTGCTGTATGATTATTGGATGTTGGAATTCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTA
TTTACACCGCATATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGATAGTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCTGACGG
GCTTGCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGTTTTACCGTCATCACCAGAACCGCGAGACG
AAAGGGCCTCGTGATACGCTATTTTTATAGGTTAATGTATGATAATAATGGTTTCTTAGACGTGAGGTGGCACTTTTCGGGAAATGTGCGCGGAACCC
CTATTTGTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCTGATAAATGCTTCAATAATATTGAAAAAGGAAGATGATGAT


Fig. 22A

24/36

ATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTGCGGCATTTTGCTTCCTGTTTTGCTCACCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA
 TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTT
 TTAAAGTTCGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGGGCAAGAGCAACTCGGTGCGCGCATACACTATTCTCAGAATGACTTGGTTGAGTAC
 TCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCT
 GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGACAAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCA
 TACCAAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAA
 TTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCGGCTGGCTGGTTATTGCTGATAAATCTGGAGCCGGTGAGCG
 TGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAA
 ATAGACAGATCGCTGAGATAGGTGCCTCACGATTAAGCATTGGTAACGTGACAGCAAGTTTACTCATATATACTTTAGATTGATTTAAACTTCATTTT
 TAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCGTAGAAAA
 GATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAACCCGCTACCAGCGGTGGTTTGTGTTGCCGGATCAAG
 AGCTACCAACTCTTTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAAATACTGTCTTCTAGTGAGCCGTAGTTAGGCCACCACTTCAAGAAC
 TCTGTAGCACCGCTACATACTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGCTTACC GGTTGGACTCAAGACGATA
 GTTACCGGATAAGGCGCAGCGGTGGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGAGCGGAACGACCTACACCGAACTGAGATACCTACAGCGTG
 AGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGG
 GGAAACGCTGGTATCTTTATAGTCCTGTGCGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAA
 CGCCAGCAACGCGGCTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTTCTTCTGCGTTATCCCTGATTCTGTGGATAACCGTATTA
 CCGCCTTTGAGTGAGCTGATACCGCTCGCCGACGCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGCAAACCGCCT
 CTCCCCGCGCGTTGGCCGATTCAATATGCAGCTGGCGCGCTCGCTCGCTCACTGAGGCGCCCGGGCAAGCCGGGCGTCGGGCGACCTTTGGTCGCC
 GGCCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACCCATCACTGAT

Fig. 22B*Fig. 23*

25/36



Time after transfection (Day) and Polarity

Fig. 24

VEGF Secretion by hRPE After Infection with VEGF AV




Fig. 25

Time after Infection (Day) and Polarity

27/36

Resistance of hRPE After Infection with VEGF AV




Fig. 26

28/36




Fig. 27

SUBSTITUTE SHEET (RULE 26)

29/36

Nucleotide Sequence of pD10-SFlt-1

AAAACCTTGGGCGCGGAATTTGACTCTAGGCCATTGCATACGTTGATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGC
CATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCCGCGTTACATAACTTACGG
TAAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCATTGAC
GTCAATGGGTGGAGTATTTACGGTAACTGCCCACTTGGCAGTACATCAAGTGATCATATGCCAAGTCCGCCCCATTGACGTCAATGACGGTAAAT
GGCCCGCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTGATGCGGT
TTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCGAAGTCTCCACCCATTGACGTCAATGGGAGTTTGTTTTGGCACCAA
ATCAACGGGACTTTCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAATGGGCGGTAGGCGGTGACGGTGGGAGGTCTATATAAGCAGAGCTCGTT
TAGTGAACCGTCAGATCGCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACGGGACCGATCCAGCCTCCGCGCGCGGAACGGTGCA
TTGGAACGCGGATTCCCGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGCATGCTATACTGTTTTGG
CTTGGGGCTTATACACCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTGACCATTATTGACCACTCCCTATTGG
TGACGATACCTTCCATTACTAATCCATAACATGGCTCTTTGCCACAATCTCTATTGGCTATATGCCAATACTCTGTCTTCAGAGACTGACACGGA
CTCTGTATTTTACAGGATGGGTCCATTTATTATTTACAAATTCACATATACAACAACGCGTCCCCGTCGCGCAGTTTTTATTAACATAGCGTG
GGATCTCCGACATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGAGCCCTGGTCCCATCCGTCCAGCGGT
CATGGTCGCTCGGCAGCTCCTTGCTCTTAACAGTGGAGGCCAGACTTAGGCACAGCACAAATGCCACCACCACAGTGTGCCGCACAAGGCCGTGGCGG
TAGGGTATGTGCTGAAAATGAGCTCGGAGATTGGGCTCGCACCTGGACGCAGATGGAAGACTTAAGGCAGCGGCAGAAGAAGATGCAGGCAGCTGAGT
TGTTGTATTCTGATAAGAGTCAGAGGTAATCCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTAGTCTGAGCAGTACTCGTTGCTGCCGCGCGCGC
CACCAGACATAATAGCTGACAGACTAACAGACTGTTCTTTCCATGGGTCTTTCTGCACTACCGTCGTCGACCTAAGAATTCCGCTTTCCACCATGG
TCAGCTACTGGGACACCGGGTCTTGCTGTGCGCGCTGCTCAGCTGTCTGCTTCTCACAGGATCTAGTTCAGGTTCAAAATTAAGATCTGAACTGA
GTTTAAAGGCACCCAGCACATCATGCAAGCAGGCCAGACACTGCATCTCCAATGCAGGGGGAAGCAGCCATAAATGGTCTTTGCTGAAATGGTGA
GTAAGGAAAGCGAAAGGCTGAGCATAACTAAATCTGCCTGTGGAAGAAATGGCAACAATTCGCACTACTTTAACCTTGAACACAGCTCAAGCAAACC
ACACTGGCTTCTACAGCTGCAAAATCTAGCTGTACCTACTTCAAAGAAGAAGGAAACAGAAATCTGCAATCTATATATTTATTAGTGATACAGGTAGAC
CTTTCTGATAGAGTGTACAGTGAATCCCGAAATTATACACATGACTGAAGGAAGGAGCTCGTCAATTCCTGCCGGGTACGTCACCTAACATCACTG
TTACTTTAAAAAGTTTCCACTTGACACTTTGATCCCTGATGGAACACGCATAATCTGGGACAGTAGAAAGGGCTTCATCATATAATGCAACGTACA
AAGAAATAGGGCTTCTGACCTGTGAAGCAACAGTCAATGGGCATTTGTATAAGACAACTATCTCACACATCGACAAACCAATACAATCATAGATGTC
AAATAAGCACACCACGCCAGTCAAACTACTTAGAGGCCATACCTTTGCTCTCAATTGTACTGCTACCACTCCCTTGAACACGAGAGTTCAATGACCT
GGAGTTACCTGATGAAAAAATAAGAGAGCTTCCGTAAGGCGACGAATTGACCAAGCAATTCATGCCAACATATTCACAGTGTCTTACTATTG
ACAAAATGCAGAACAAAGACAAAGGACTTTATACCTTGCTGTAAGGAGTGGACCATCATCAAACTGTTAACACCTCAGTGCATATATATGATAAG
CATTCACTACTGTGAAACATCGAAAACAGCAGGTGCTTGAAACCGTAGCTGGCAAGCGGTCTTACCGGCTCTCTATGAAAGTGAAGGCATTTCCCTCGC
CGGAAGTTGTATGGTTAAAGATGGGTACCTGCGACTGAGAAATCTGCTCGCTATTTGACTCGTGGCTACTCGTTAATTATCAAGGACGTAACCTGAAG
AGGATGCAGGGAATTATACAATCTTGCTGAGCATAAAACAGTCAAAATGTGTTTAAAAACCTCACTGCCACTCTAATTGTCAATGTGAAACCCAGATTT
ACGAAAAGGCCGTGCATCGTTTCCAGACCCGGCTCTTACCCACTGGGCAGCAGACAAATCCTGACTTGTACCGCATATGGTATCCCTCAACCTACAA
TCAAGTGGTTCTGGCACCCCTGTAACCAATAATCCTCGAAGCAAGGTGTGACTTTTGTGTTCCAATAATGAAGAGTCCCTTATCCTGGATGCTGACAGCA
ACATGGGAAACAGAATTGAGAGCATCACTCAGCGCATGGCAATAATAGAAGGAAGAATAAGATGGCTAGCACCTTGGTTGTGGCTGACTCTAGAATTT
CTGGAATCTACATTTGCATAGCTTCCAATAAAGTTGGGACTGTGGGAAGAAACATAAGCTTTTATATCACAGATGTGCCAAATGGGTTTCATGTTAACT
TGGAAAAATGCCGACGAAGGAGAGGACCTGAAACTGTCTTGACAGTTAACAAGTTCTTATACAGAGACGTTACTTGGATTTTACTGCGGACAGTTA
ATAACAGAACAATGCACTACAGTATTAGCAAGCAAAAAATGGCCATCACTAAGGAGCACTCCATCACTCTTAATCTTACCATCATGAATGTTTCCCTGC
AAGATTCAGGCACCTATGCCGTCAGAGCCAGGAATGTATACAGGGGAAGAAATCCTCCAGAAGAAAGAAATTAACAATCAGAGGTGAGCACTGCAACA
AAAAGGCTGTTTTCTCTCGATCTCCAAATTTAAAGCACAAAGGAATGATTGTACCACAAAGTAATGTAAACATTAAAGGACTCATTAAAAAGTAA
CAGTTGCTCATATCATCTTGATTTATTGTCACTGTTGCTAACTTTACGGCTCAAGGCGAATTACGGCTAAGCTTCTAGGTATCGATCTCGAGCAA
GTCTAGAAAGCCATGGATATCGGATCCACTACGCGTTAGAGCTCGCTGATCAGCCTCGACTGTGCTTCTAGTTGCCAGCCATCTGTTGTTGCCCTC

Fig. 28A

SUBSTITUTE SHEET (RULE 26)

30/36

CCCCGTGCGCTTCTTGACCCGTGAAGGTGCCACTGCCACTGTCTTCTTAATAAAATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTAT
TCTGGGGGGTGCGGTGGGGCAGGACAGCAAGGGGGAGGATTGGGAAGACAATAGCAGGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCCGGCTGGA
GGATCATCCAGCTAGCAAGTCCCATCAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTGCCCCGA
CGCCCGGGCTTTGGCCGGGCGGCTCAGTGAGCGAGCGAGCGCCAGCGATTCTCTTGTTTGTCTCCAGACTCTCAGGCAATGACCTGATAGCCTTGT
AGAGACCTCTCAAAAATAGCTACCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTGACTGTCTCCGGCTTTCT
CACCCGTTTGAATCTTTACCTACACATTACTCAGGCATTGCATTTAAATATATGAGGGTTCTAAAAATTTTATCCTTGGCTTGAATAAAGGCTTCT
CCCGCAAAAGTATTACAGGGTCATAATGTTTTGGTACAACCGATTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGTAAATCTTTGCTTGC
CTGTATGATTTATTGGATGTTGGAATTCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATTTACACCGCATATGGTGCACCTCTCAGTACAAT
CTGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACCCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACA
AGCTGTGACCGCTCTCCGGGAGCTGCATGTGTGAGAGGTTTTACCCGTCATACCGAAACGCGCGAGACGAAAGGGCTCGTGATACGCCTATTTTTATA
GGTTAATGTGATGATAAATGGTTTTCTAGACGTGAGTGGCACTTTTCGGGGAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTC
AAATATGTATCCGCTCATGAGACAATAACCCGTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATGAGTATTCAACATTTCCGTGTGCGCCCTAT
TCCCTTTTTTGCGGCATTTTCCCTTCTGTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTA
CATCGAACTGGATCTCAACAGCGGTAAAGTCCCTGAGAGTTTCCGCCCGAAGAACGTTTCCAAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGC
GGTATTATCCGCTATTGACGCCGGGCTGAGCAACTCGGTGCGCGCATACACTATTCTCAGAAATGACTTGGTTGAGTACTCACCAGTCACAGAAAGCA
TCTTACGGATGGCATGACAGTAAGAGATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCAACTTACTTCTGACAACGATCCGAGGACC
GAAGGAGCTAACCGCTTTTTTGACAACATGGGGGATCATGTAACCTCGCTTGATCGTTGGGAACCGAGCTGAATGAAGCCATACCAAACGACGAGCG
TGACACCAGGATGCCGTGAGCAATGGCAACAACGTTGCGCAAACTATTAACGTGGCAACTACTTACTCTAGCTTCCCGCAACAATTAATAGACTGGAT
GGAGGCGGATAAAGTTGACGAGCACCTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGG
TATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGAT
CGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACGTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAACCTCATTTTTAATTTAA
AAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAA
AGGATCTTCTTGAGATCCTTTTTCTGCGCGTAATCTGCTGCTTGCAACAAAAAACCCGCTACCAGCGGTGGTTTGTGTCGGGATCAAGAGCT
ACCAACTCTTTTTCCGAAGGTAACGGCTTCAGCAGAGCGCAGATACCAAACTGCTCTTCTAGTGTAGCCGTAGTTAGGCCACCCTTCAAGAATC
TGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACAGTGGCTGCTGCCAGTGGCGATAAGTCGTGCTTACCGGGTTGACTCAAGACGATA
GTTACCGGATAAGGCGCAGCGGTGCGGCTGAACGGGGGGTTCGTGCACACAGCCAGCTTGGAGCGAACGACCTACACCGAACTGAGATACCTACAGCG
TGAGCTATGAGAAAGCGCCACGCTTCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGCGCACGAGGGAGCTTCC
AGGGGGAACGCGCTGGTATCTTTATAGTCTGTGCGGTTTCCGCCCTCTGACTTGAGCGTCGATTTTGTGATGCTCGTCAGGGGGGCGGAGCTATG
GAAAAACGCCAGCAACGCGGCTTTTTACGGTTCTTGCCCTTTTGTGCGCTTTTGTGCTCACATGTTCTTTCTGCGTTATCCCTGATTCTGTGGATAA
CCGTATTACCGCTTTGAGTGAGCTGATACCGCTCGCCGACGCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACG
CAAACCGCCTCTCCCGCGCGTTGGCCGATTCAATTAATGCAGCTGGCGCGCTCGCTCGCTCACTGAGGCGCGCCGGGCAAGCCGGGCTGCGGCGAC
CTTTGGTCGCCCGCCTCAGTGAGCGAGCGAGCGCGCAGAGGGAGTGGCCAACCTCATCACTGAT

Fig. 28B

SUBSTITUTE SHEET (RULE 26)

31/36

HumanFGF-20

atggctcccttagccgaagtcgggggctttctgggcggcctggagggttgagccagcag
N A P L A E V G G F L G G L E G L G Q Q

gtgggttcgcatttcctgttgccctcctgccggggagcggccgccgtgctgggcgagcgc
V G S H F L L P P A G E R P P L L G E R

aggagcgcggcgaggcggagcgcgcggcgggccgggggtgcgcagctggcgacctg
R S A A E R S A R G G P G A A Q L A H L

cacggcatcctgcggccggcagctctatigccgcaccggctccacctgcagatcctg
H G I L R R R Q L Y C R T G F H L Q I L

cccgacggcagcgtgcagggcacccggcaggaccacagcctcttcggtatcttgaattc
P D G S V Q G T R Q D H S L F G I L E F

atcagtgtggcagtgaggactggcagctattagaggtgtggacagtggtctctatcttga
I S V A V G L V S I R G V D S G L Y L G

atgaatgacaaaggagaactctatggatcagagaaacttacttccgaatgcatctttagg
M N D K G E L Y G S E K L T S E C I F R

gagcagitttgaagagaactgggtataacacctattcatctaacaatataaaacatggagac
E Q F E E N W Y N T Y S S N I Y K H G D

actggccgcaggatatttggcacttaacaaagacggaactccaagagatggcgccagg
T G R R Y F V A L N K D G T P R D G A R

tccaagaggcatcagaaatttacacatttcttacctagaccagtggtccagaaagagtt
S K R H Q K F T H F L P R P V D P E R V

ccagaattgtacaaggacctactgatgtacacttga
P E L Y K D L L M Y T

Fig. 29

SUBSTITUTE SHEET (RULE 26)

32/36

Mouse FGF-21 cDNA in pGEM-T

gagcgcagccctgatggaatggatgagatctagagttgggaccctgggactgtgggtccg SEQ ID NO: 1
M E W M R S R V G T L G L W V R SEQ ID NO: 2

actgctgctggctgtcttcctgctgggggtctaccaagcatacccatccctgactccag
L L L A V F L L G V Y Q A Y P I P D S S

ccccctctccagtttgggggtcaagtcggcagaggtacctctacacagatgacgacca
P L L Q F G G Q V R Q R Y L Y T D D D Q

agacactgaagcccacctggagatcaggagggatggaacagtggtaggcgcagcacaccg
D T E A H L E I R E D G T V V G A A H R

cagtcagaaagtctcctggagctcaaagcctgaagccaggggtcattcaaattcctggg
S P E S L L E L K A L K P G V I Q I L G

tgtcaaagcctctaggtttctttgccaacagccagatggagctctctatggatgcctca
V K A S R F L C Q Q P D G A L Y G S P H

ctttgatcctgaggcctgcagcttcagagaactgctgctggaggacgggtacaattgtga
F D P E A C S F R E L L L E D G Y N V Y

ccagtcctgaagcccatggcctgccctgcgtctgcctcagaaggactccccaaaccagga
Q S E A H G L P L R L P Q K D S P N Q D

tgcaacatcctggggacctgtgcgttcctgccatgccaggcctgtccacgagcccca
A T S W G P V R F L P M P G L L H E P Q

agaccaagcaggattcctgccccagagccccagatgtgggtcctctgacccctgag
D Q A G F L P P E P P D V G S S D P L S

catggtagagcctttacagggccgaagccccagctatgcgtcctgactcttcctgaatc
M V E P L Q G R S P S Y A S

Fig. 30

SUBSTITUTE SHEET (RULE 26)

33/36




Fig. 31

SUBSTITUTE SHEET (RULE 26)

34/36

AAAAC TTGCGGCCGCGGAATTCGACTCTAGGCCATTGCATACGTTGTATCTATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACC
GCCATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATATGGAGTTCGCGGTACATAACTT
ACGGTAATGGCCCGCTGGCTGACCGCCCAACGACCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCC
ATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGA
CGGTAAATGGCCCGCTGGCATTATGCCAGTACATGACCTTACGGGACTTTCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATG
GTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGT
TTTGGCACC AAAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCGTTGACGCAAATGGGCGGTAGGCGGTACGGTGGGAGGTCTATAT
AAGCAGAGCTCGTTTAGTAACCGTCAGATCGCCTGGAGACGCCATCCACGCTGTTTGGCTCCATAGAAGACACCGGGACCGATCCAGCCTCCGC
GGCCGGGAACGGTGCATTGGAACGGGATTCCCGTGCCAAGAGTGACGTAAGTACCGCTATAGACTCTATAGGCACACCCCTTTGGCTCTTATGC
ATGCTATACTGTTTTTGGCTTGGGGCTATACACCCCGCTCCTTATGCTATAGGTGATGGTATAGCTTAGCCTATAGGTGTGGGTATTGACCATT
ATTGACCAC TCCCTATTGGTGACGATCTTCCATTACTAATCCATAACATGGCTCTTTGCCACAATATCTCTATTGGCTATATGCCAATCTCT
GTCTTCAGAGACTGACACGGACTCTGTATTTTACAGGATGGGTCCATTATTATTTACAAATTCACATATACAACAACCGCTCCCGCTGCC
GCAGTTTTTATTAACATAGCGTGGGATCTCCGACATCTCGGGTACGTGTTCCGGACATGGGCTCTTCTCCGGTAGCGGCGGAGCTTCCACATCCGA
GCCCTGGTCCCATCCGTCCAGCGGCTTATGGTCGCTCGGCAGCTCTTGCTCCTAACAGTGGAGGCCAGACTTAGGCACAGCAATGCCACCACC
ACCAGTGTGCCGACAAGGCGTGGGGTAGGGTATGTGTCTGAAAATGAGCTCGGAGATTGGGCTCGCACCTGGACGCAGATGGAAGACTTAAGGC
AGCGGCAGAAGAAGATGCAGGCAGCTGAGTTGTTGATTCTGATAAGAGTCAGAGGTAACCTCCGTTGCGGTGCTGTTAACGGTGGAGGGCAGTGTA
GTCTGAGCAGTACTCGTTGCTGCCGCGCGCCACCAGACATAATAGTGACAGACTAACAGACTGTTCTTTCCATGGGTCTTTTCTGCAGTCACC
GTCTGACCTAAGAATTCAAGTATGGCTGCTGTTCTATCACTACCCTGCCAGCTCTGCCAGAAGACGGTGGTCTGGTGCCTTCCACCAGGTCA
CTTCAAAGACCCAAAACGTCTGTACTGCAAAAACGGTGGTTTCTTCTGCGCATCCACCCGACGGCCGAGTGGACGGGTCCGCGAGAAGAGCGAC
CCACACATCAAAC TACAAC TTAAGCAGAAGAGAGAGGGGTGTGTCTATCAAAGGAGTGTGTGCAAACCGTTACCTTGCTATGAAAGAAGATGGAA
GATTACTAGCTTCTAAATGTGTTACAGACGAGTGTCTTTTGAACGATTGGAGTCTAATAACTACAATACCTACCGGTCAAGGAAATACACCAG
TTGGTATGTGGCACTGAAACGAAC TGGCAGTATAAACTTGGATCCAAAACAGGACCTGGGCAGAAAGCTATACTTTTTCTTCCAATGTCTGCTAAG
AGCTGATCTTAATGGCAGCATCTGATCTCATTTTACATGAAGCTTCTAGGTATCGATCTCGAGCAAGTCTAGAAAGCCATGGATATCGGATCCACT
ACGCGTTAGAGCTCGCTGATCAGCCTCGACTGTGCTTCTAGTTGCCAGCATCTGTTGTTTGCCCTCCCGCTGCCCTTCTTGACCTGGAAGGT
GCCACTCCCACTGTCTTTCTAATAAAAATGAGGAAATGCATCGCATTGTCTGAGTAGGTGTATTCTATTCTGGGGGTGGGGTGGGCAGGACA
GCAAGGGGGAGGATTGGGAAGACAATAGCAGGGGGTGGGCGAAGAACTCCAGCATGAGATCCCGCGCTGGAGGATCATCCAGCTAGCAAGTCCCA
TCAGTGATGGAGTTGGCCACTCCCTCTCTGCGGCTCGCTCGCTCACTGAGGCCGGGCGACCAAGGTGCGCCGACGCCCGGGCTTTGCCGGGCGG
CCTCAGTGAGCGAGCGAGCGCGCCAGCGATTCTCTGTTTGTCTCCAGACTCTCAGGCAATGACCTGATAGCCTTTGTAGAGACCTCTCAAAAATAGC
TACCCTCTCCGGCATGAATTTATCAGCTAGAACGGTTGAATATCATATTGATGGTGATTGACTGTCTCCGGCTTTCTCACCCGTTTGAATCTTTA
CCTACACATTACTCAGGCATTGCATTTAAATATATGAGGGTTCTAAAAATTTTATCCTTGCGTTGAAATAAAGGCTTCTCCCGCAAAGTATTAC
AGGGTCATAATGTTTTTGGTACAACCGATTAGCTTTATGCTCTGAGGCTTTATTGCTTAATTTTGCTAATTTCTTGCTTGCCTGTATGATTATT
GGATGTTGGAATTCCTGATGCGGTATTTCTCCTTACGCATCTGTGCGGTATTTACACCCCATATGGTGCACCTCAGTACAATC

Fig. 32A

SUBSTITUTE SHEET (RULE 26)

35/36

TGCTCTGATGCCGCATAGTTAAGCCAGCCCCGACACCCGCCAACCCCGTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGAC
AAGCTGTGACCGTCTCCGGGAGCTGCATGTGTGAGAGGTTTTCACCGTCATACCGAAACGCGGAGACGAAAGGGCTCGTGATACGCTATTTTT
ATAGGTTAATGTATGATAAATAATGGTTTCTTAGACGTGAGGTGGCACTTTTCGGGAAATGTGCGCGGAACCCCTATTTGTTATTTTCTAAATA
CATTCAAATATGTATCCGCTCATGAGACAATAACCCGTATAAATGCTTCAATAATGTACCGGTCAAGAAGGCGATAGAAGGCGATGCGTGGCAATC
GGGAGCGGCGATACCGTAAAGCAGGAGGAAGCGGTGAGCCCATTCGCTTCAGCAATATCACGGGTAGCCAACGCTATGCTCTGATAGCGGTCCGCCA
CACCCAGCGCGGCACAGTCGATGAATCCAGAAAAGCGGCCATTTTCCACCATGATATTCGGCAAGCAGGCATCGCCATGGGTACGACGAGATCCTC
GCCGTGCGGCATGCGCGCTTGAGCCTGGCGAACAGTTTCGGCTGGCGCGAGCCCTGATGCTCTTCGTCCAGATCATCTGATCGACAAGACCGGCT
TCCATCCGAGTACGTGCTCGCTCGATGCGATGTTTCGCTTGGTGGTGAATGGGCAGGTAGCCGGATCAAGCGTATGCAGCCGCCGATTGCATCAG
CCATGATGGATACTTTCTCGGCAGGAGCAAGGTGAGATGACAGGAGATCCTGCCCGGCACTTCGCCCAATAGCAGCCAGTCCCTTCCCGCTTCAGT
GACAACGTGAGCAGACAGTGCAGCAAGGAACGCCGTCGTGGCCAGCCACGATAGCCGCGCTGCCTCGTCTGCAGTTCATTAGGGACCGGACAGG
TCGGTCTTGACAAAAAGAACCGGGCGCCCCGCGCTGACAGCCGAACACGGCGGCATCAGAGCAGCCGATTGTCTGTTGTGCCAGTCATAGCCGA
ATAGCCTCTCCACCAAGCGGCGGAGAACCTGCGTGCAATCCATCTTGTTCAATCATGCGAAACGATCCTCATCTGTCTCTTGATCAGATCTTGA
TCCCTCGGCCATCAGATCCTTGCGGCAAGAAAGCCATCCAGTTTACTTTGAGGGCTTCCCAACCTTACCAGAGGGCGCCCGAGTGGCAATTCC
GGTTGCTTGTGTCATAAAACCGCCAGTCTAGCTATCGCCATGTAAGCCCACTGCAAGCTACCTGCTTTCTCTTTGCGCTTGGCTTTTCCCTG
TCCAGATAGCCAGTAGCTGACATTCATCCGGGTGAGCAGCGTTTCTGCGGACTGGCTTTCTACGTGTTCCGCTTCTTTAGCAGCCCTTGGCGCC
TGAGTGCTTGGCGAGCGTGAAGCTGTCAATTCGCGTTAAATTTTGTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCT
TATAAATCAAAGAATAGCCCGAGATAGGGTTGAGTGTTGTTCCAGTTTGAACAAGAGTCCACTATTAAGAAGCTGGACTCCAACGTCAAAGGGC
GAAAAACCGTCTATCAGGGCGATGGCGGATCAGCTTATGCGGTGTGAATACCGCACAGATGCGTAAGGAGAAAAATACCGCATCAGGCGCTCTTCG
CTTCTCGCTCACTGACTCGCTGCGCTCGGTGCTGCGGTGCGGCGAGCGGTATCAGCTCACTCAAGGCGGTAAACGTTATCCACAGAATCAGG
GGATAACGCAGGAAGAACATGCGGCGGCCACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCGCGTGTGCTGGCGTTTTTCC
ATAGGCTCCGCCCCCTGACGAGCATCAGAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAGATACCAGGCGTTTCCCC
TGGAAGCTCCCTCGTGCGCTCTCTGTTCCGACCTGCGCTTACCGGATACCTGTCCGCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGC
TCACGCTGTAGGTATCTCAGTTCGGTGTAGGTGTTGCTCCAAGCTGGGCTGTGTGACGAACCCCCCGTTACGCCCAGCGCTGCGCTTATCCG
GTAATATCGTCTTGAGTCCAACCCGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGAGGTATGTAGGCGG
TGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGAAAA
AGAGTTGGTAGCTCTTGATCCGGCAAAACAAACCCGCTGGTAGCGGCGGTTTTTTGTTTGAAGCAGCAGATTACGCGCAGAAAAAAGGATCTCA
AGAAGATCCTTTGATCTTTTCTTACTGAACGGTGATCCCCACCGGAATTGCGGCCATGTTCTTCTGCGTTATCCCCGATTCTGTGGATAACCG
TATTACCGCTTTGAGTGAGCTGATACCGCTCGCGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCCAATACGC
AAACCGCTCTCCCGCGCGTTGGCCGATTCTTAATGACAGCTGGCGCGCTCGCTCGCTCACTGAGGCCGCCCGGCAAGCCCGGCGTGGGCGA
CCTTTGGTCCGCCGCGCTCAGTGAGCGAGCGAGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTGAT

Fig. 32B

SUBSTITUTE SHEET (RULE 26)




Fig. 33

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
21 September 2000 (21.09.2000)

PCT

(10) International Publication Number
WO 00/54813 A3

(51) International Patent Classification⁷: **A61K 48/00**,
C12N 15/00, 15/63, 15/86, A61P 25/00, 27/00

(21) International Application Number: PCT/US00/07062

(22) International Filing Date: 15 March 2000 (15.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/124,460 15 March 1999 (15.03.1999) US
60/174,984 6 January 2000 (06.01.2000) US

(71) Applicants (for all designated States except US): **CHIRON CORPORATION** [US/US]; 4560 Horton Street, Emeryville, CA 94608 (US). **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 12th floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MANNING, William, C., Jr.** [US/US]; 3660 Country Club Drive, Redwood City, CA 94061 (US). **DWARKI, Varavani, J.** [US/US]; 1177 Old Alameda Point, Alameda, CA 94502 (US). **RENDAHL, Katherine** [US/US]; 1221 Grizzly Peak Boulevard, Berkeley, CA 94708 (US). **ZHOU, Shang-Zhen** [US/US]; 125 Fundy Bay, Alameda, CA 94502 (US). **MCGEE, Laura, H.** [US/US]; 652 54th Street, Oakland, CA 94609 (US). **LAU, Dana** [US/US]; Apartment A, 280 Lenox Avenue, Oakland, CA 94610 (US). **FLANNERY, John, G.** [US/US]; 1728 Marin

Avenue, Berkeley, CA 94707 (US). **MILLER, Sheldon** [US/US]; 186 Hillcrest Road, Berkeley, CA 94705 (US). **WANG, Fei** [CN/US]; 981 9th Street, Albany, CA 94710 (US). **DI POLO, Adriana** [VE/US]; 704 Champagneur Avenue, Outremont, Quebec H2V 3P8 (CA).

(74) Agents: **MCMASTERS, David, D.** et al.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 5th Avenue, Seattle, WA 98104-7092 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:
3 May 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF RECOMBINANT GENE DELIVERY VECTORS FOR TREATING OR PREVENTING DISEASES OF THE EYE

(57) Abstract: Gene delivery vectors, such as, for example, recombinant adeno-associated viral vectors, and methods of using such vectors are provided for use in treating or preventing diseases of the eye.

WO 00/54813 A3

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/07062

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K48/00 C12N15/00 C12N15/63 C12N15/86 A61P25/00
A61P27/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, CHEM ABS Data, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 00 15822 A (JANSSEN JACQUES J ;CATHOLIC UNIVERSITY NIJMEGEN (NL); HAUSWIRTH WI) 23 March 2000 (2000-03-23) * see claims 1, 13-15, 21, 31-32 and page 37 *	1-6, 8, 9, 16, 22-25, 29
X, P	WO 00 01815 A (BLOM NIKOLAJ ;HANSEN CLAUS (DK); JOHANSEN TEIT E (DK); NEUROSEARCH) 13 January 2000 (2000-01-13) * see page 1, page 28 lines 4-8, page 24 lines 6-11 and page 25 line 25 to page 26 line 30 *	1, 5, 6, 8, 9, 22, 27
X	US 5 641 749 A (YAN QIAO ET AL) 24 June 1997 (1997-06-24)	1, 2, 9, 22, 23
Y	* see claims 1-2, 11 and col.16 line 62 to col.17 line 42 *	1-16, 22-25, 27-29
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

21 December 2000

Date of mailing of the international search report

15.01.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gore, V

INTERNATIONAL SEARCH REPORT

International Application No

PC1/US 00/07062

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 26409 A (ABITBOL MARC ;MALLET JACQUES (FR); REVAH FREDERIC (FR); ROUSTAN PA) 5 October 1995 (1995-10-05)	1, 3, 4, 22, 24, 25
Y	* see claims 1, 9, 17, 20, page 10 lines 10-19 and page 11 lines 11-15 *	1-16, 22-25, 27-29
X	--- CAYOINETTE M ET AL.: "ADENOVIRUS-MEDIATED GENE TRANSFER OF CILIARY NEUROTROPHIC FACTOR CAN PREVENT PHOTORECEPTOR DEGENERATION IN THE RETINAL DEGENERATION (RD) MOUSE" HUMAN GENE THERAPY, XX, XX, vol. 8, no. 4, 1 March 1997 (1997-03-01), pages 423-430, XP000876513 ISSN: 1043-0342 * see abstract, pages 424 and 429 *	1-4, 8, 22, 24, 25
X	--- AKIMOTO ET AL.: "Adenovirally expressed basic fibroblast growth factor rescues photoreceptor cells in RCS rats." IOVS, vol. 40, February 1999 (1999-02), pages 273-279, XP000917329	1, 3, 4, 22, 24, 25
Y	* see abstract, pages 274 and 278 *	1-16, 22-25, 27-29
X	--- PETERSON ET AL.: "Enhanced survival of photoreceptors in p23h mutant rhodopsin transgenic rats by adeno-associated virus (AAV)-mediated delivery of neurotrophic genes." IOVS, vol. 39, 15 March 1998 (1998-03-15), page S1117 XP000917442 * see abstract *	1, 2, 16, 22, 23, 29
X, P	--- WO 99 45952 A (GENENTECH INC) 16 September 1999 (1999-09-16) * see abstract, page 13 and pages 19-20 *	22
Y	--- LUTHER ET AL.: "Photoreceptor rescue." EYE, vol. 12, June 1998 (1998-06), pages 591-596, XP000917332 London * see abstract, page 593 right col. and page 594 left col. *	1-16, 22-25, 27-29
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07062

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO 99 16889 A (BOLANOWSKI MARK A ;SEARLE & CO (US); CAPARON MAIRE H (US); GREGORY) 8 April 1999 (1999-04-08)	22, 27
Y	* see abstract, page 5 lines 1-4, page 16 lines 21-25 *	17-21, 26, 28, 29
X	WO 98 51323 A (STRUMAN INGRID ;MARTIAL JOSEPH A (BE); TAYLOR ROBERT (US); UNIV CA) 19 November 1998 (1998-11-19)	22, 27-29
Y	* see abstract, page 8 lines 1-12 and pages 16-17 *	17-21, 26
X	EP 0 407 122 A (REPLIGEN CORP) 9 January 1991 (1991-01-09)	22
Y	* see abstract and page 4 lines 10-16 *	17-21, 26-29
X	US 5 792 845 A (FOLKMAN M JUDAH ET AL) 11 August 1998 (1998-08-11)	22
Y	* see col. 4 lines 33-46, col. 5 line 59 to col. 6 line 5, cl. 8 *	17-21, 26-29
X	DATABASE WPI Section Ch, Week 199925 Derwent Publications Ltd., London, GB; Class B04, AN 1999-296483 XP002156115 & JP 11 100327 A (TORAY IND INC), 13 April 1999 (1999-04-13)	22, 26, 27
Y	abstract	17-21, 28, 29
X	WO 98 13071 A (KENDALL RICHARD L ;THOMAS KENNETH A JR (US); BETT ANDREW J (US); G) 2 April 1998 (1998-04-02)	22, 26-29
Y	* see abstract, cl. 21 and page 18 *	17-21
Y	SMITH L.E.H. ET AL.: "Inhibition of retinal neovascularization with an IGF-1 receptor antagonist." IOVS, vol. 39, 1998, page S450 XP000944951 * abstract *	17-22, 26-29
Y	SHAFIEE A. ET AL.: "Thrombospondin peptides inhibit angiogenesis in retinal explant assay and rat model of retinopathy of prematurity." IOVS, vol. 38, 1997, page S964 XP000944952 * abstract *	17-22, 26-29
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/07062

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	FOTSIS T. ET AL.: "The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth." NATURE, vol. 368, 1994, pages 237-239, XP002046111 * abstract *	17-22, 26-29
Y	--- OIKAWA ET AL. : "Three novel synthetic retinoids, RE 80, AM 580 and AM 80, all exhibit anti-angiogenic activity in vivo." EUROPEAN JOURNAL OF PHARMACOLOGY., vol. 249, 1993, pages 113-116, XP000879175 * abstract *	17-22, 26-29

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/07062

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Rule 39.1(iv) PCT. Although claims 1-21 are directed to methods of treatment of the animal or human body, the search was carried out on the alleged therapeutic effects of the compounds of the application.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-16, 22 (part), 23-25, 27-29 (part)

Use of an expression vector encoding a neurotrophic factor (claims 1-16, claim 22 (part), claims 23-25, claims 27-29 (part)).

2. Claims: 17-21, 22 (part), 26, 27-29 (part)

Use of an expression vector encoding a anti-angiogenic factor (claims 17-21, claim 22 (part), claim 26, claims 27-29 (part)).

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC1/US 00/07062

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0015822 A	23-03-2000	AU 6394199 A	03-04-2000
WO 0001815 A	13-01-2000	AU 4769399 A	24-01-2000
US 5641749 A	24-06-1997	AT 194081 T	15-07-2000
		AU 696772 B	17-09-1998
		AU 1163197 A	19-06-1997
		BR 9611748 A	01-06-1999
		CN 1203531 A	30-12-1998
		CZ 9801499 A	12-08-1998
		DE 69609084 D	03-08-2000
		DE 69609084 T	16-11-2000
		EP 0866719 A	30-09-1998
		ES 2148826 T	16-10-2000
		HU 0001078 A	28-08-2000
		JP 2000501393 T	08-02-2000
		NO 982276 A	29-07-1998
		SK 65898 A	11-01-1999
		WO 9719695 A	05-06-1997
WO 9526409 A	05-10-1995	FR 2718150 A	06-10-1995
		AU 2142595 A	17-10-1995
		CA 2184755 A	05-10-1995
		EP 0753067 A	15-01-1997
		JP 9510621 T	28-10-1997
		ZA 9502563 A	21-12-1995
WO 9945952 A	16-09-1999	AU 3081399 A	27-09-1999
WO 9916889 A	08-04-1999	AU 9673998 A	23-04-1999
		EP 1019515 A	19-07-2000
WO 9851323 A	19-11-1998	AU 7383298 A	08-12-1998
EP 0407122 A	09-01-1991	US 5112946 A	12-05-1992
		AT 143698 T	15-10-1996
		CA 2019086 A	06-01-1991
		DE 69028739 D	07-11-1996
		DE 69028739 T	13-02-1997
		DK 407122 T	17-02-1997
		EP 0723015 A	24-07-1996
		ES 2092493 T	01-12-1996
		GR 3021658 T	28-02-1997
		JP 3063297 A	19-03-1991
US 5792845 A	11-08-1998	US 5639725 A	17-06-1997
		AU 692865 B	18-06-1998
		AU 2461795 A	16-11-1995
		BR 9507479 A	16-09-1997
		CA 2188813 A	02-11-1995
		CN 1149319 A	07-05-1997
		CZ 9603122 A	14-05-1997
		EP 0758390 A	19-02-1997
		HU 76095 A	30-06-1997
		JP 9512173 T	09-12-1997
		NZ 285501 A	26-02-1998
		WO 9529242 A	02-11-1995
		US 5885795 A	23-03-1999

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/07062

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5792845 A		US 5733876 A	31-03-1998
		US 5776704 A	07-07-1998
		ZA 9503419 A	11-01-1996
JP 11100327 A	13-04-1999	NONE	
WO 9813071 A	02-04-1998	AU 4650397 A	17-04-1998
		EP 0928203 A	14-07-1999

THIS PAGE BLANK (user)